Key Takeaways CF generated $496M in operating cash flow in Q1, backed by strong operational execution.CF returned $1.7B to its shareholders in 2025, including $1.34B in share repurchases.CF's 2025 free cash flow rose 24% year over year to $1.79B amid strong nitrogen demand. CF Industries Holdings, Inc. (CF - Free Report) generated healthy cash flows in the first quarter, backed by strong operational performance, strategic execution and supportive nitrogen industry fundamentals. Its net cash provided by operating activities was $496 million for the quarter. Its cash and cash equivalents were roughly $2 billion at the end of the quarter.
Notably, CF generated net cash from operating activities of $2.75 billion and free cash flow of $1.79 billion in 2025, up roughly 21% and 24% year over year, respectively.
CF’s substantial cash flows and strong balance sheet enable it to finance its strategic growth investment, pay down debt and drive shareholder value. CF returned $1.7 billion to its shareholders in 2025. It repurchased 16.6 million shares for $1.34 billion during 2025. Since the commencement of its current $2 billion buyback program in October 2025, CF Industries has bought back 3.6 million shares for around $293 million.
The company is efficiently converting adjusted EBITDA to free cash flow. Its full-year 2025 free cash flow to adjusted EBITDA conversion rate was 62%, outpacing sector averages. The same for the first quarter was 51%.
The company is expected to continue generating significant free cash flow, leveraging its high-margin business, strategic execution and favorable global nitrogen industry dynamics, allowing it to invest in growth opportunities and enhance returns to its shareholders.
Among its peers, Nutrien Ltd. (NTR - Free Report) generated solid cash flows in the first quarter, thanks to higher fertilizer benchmark pricing, increased retail earnings and record potash sales volumes. NTR’s cash provided in operating activities was $851 million in the first quarter. Nutrien generated an operating cash flow of $4 billion for full-year 2025.
The Mosaic Company’s (MOS - Free Report) cash flow from operating activities was $104.2 million in the first quarter, up from $42.9 million a year ago, aided by improved working capital dynamics. Mosaic’s free cash flow was negative $252.6 million, consistent with typical first-quarter seasonality. MOS generated an operating cash flow of $825 million in 2025.
CF’s Price Performance, Valuation & EstimatesCF Industries has gained 22.7% in the past year compared with the Zacks Fertilizers industry’s rise of 4.4%.
Image Source: Zacks Investment Research
From a valuation standpoint, CF is currently trading at a forward 12-month earnings multiple of 7.71, a 36.8% discount relative to the industry average of 12.21X. It carries a Value Score of B.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for CF’s 2026 and 2027 earnings implies a year-over-year rise of 87.5% and a decline of 38.9%, respectively. The EPS estimates for 2026 and 2027 have been trending higher over the past 60 days.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving room for profits.
On top of the Zacks Rank, investors can also look at our innovative Style Scores system to find stocks with specific traits. For example, value investors will want to focus on the "Value" category. Stocks with high Zacks Ranks and "A" grades for Value will be some of the highest-quality value stocks on the market today.
One company value investors might notice is CF Industries (CF - Free Report) . CF is currently sporting a Zacks Rank #1 (Strong Buy) and an A for Value. The stock holds a P/E ratio of 11.87, while its industry has an average P/E of 12.26. Over the past 52 weeks, CF's Forward P/E has been as high as 16.16 and as low as 11.10, with a median of 14.29.
Investors should also note that CF holds a PEG ratio of 0.39. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. CF's industry has an average PEG of 0.76 right now. Within the past year, CF's PEG has been as high as 2.67 and as low as 0.30, with a median of 0.67.
We should also highlight that CF has a P/B ratio of 1.84. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. CF's current P/B looks attractive when compared to its industry's average P/B of 2.41. CF's P/B has been as high as 2.38 and as low as 1.59, with a median of 1.93, over the past year.
Finally, investors will want to recognize that CF has a P/CF ratio of 6.29. This figure highlights a company's operating cash flow and can be used to find firms that are undervalued when considering their impressive cash outlook. CF's P/CF compares to its industry's average P/CF of 9.61. CF's P/CF has been as high as 8.02 and as low as 5.19, with a median of 6.93, all within the past year.
Investors could also keep in mind Yara International ASA (YARIY - Free Report) , another Fertilizers stock with a Zacks Rank of #2 (Buy) and Value grade of A.
Furthermore, Yara International ASA holds a P/B ratio of 1.15 and its industry's price-to-book ratio is 2.41. YARIY's P/B has been as high as 1.36, as low as 0.87, with a median of 1.08 over the past 12 months.
These are only a few of the key metrics included in CF Industries and Yara International ASA strong Value grade, but they help show that the stocks are likely undervalued right now. When factoring in the strength of its earnings outlook, CF and YARIY look like an impressive value stock at the moment.
Investors with an interest in Chemical - Diversified stocks have likely encountered both LyondellBasell (LYB) and Albemarle (ALB). But which of these two stocks is more attractive to value investors?
LyondellBasell is no longer attractive after a significant dividend cut and updated valuation. Recent EBITDA growth in key segments is driven by unsustainable geopolitical factors, not fundamental improvements. The technology segment's unpredictable earnings and high debt levels heighten risk, especially in a volatile rate environment.
Most high-yield dividend investors think diversification alone can protect them from landmines. Others focus on the dividend payout ratio. However, there are far more important factors to look at when evaluating a dividend stock.
LyondellBasell no longer offers a high-dividend yield following a 50% dividend cut. Its operating momentum has improved greatly due to supply chain disruptions in the Middle East. The dividend is now sustainable, but a dividend yield of 3.85% doesn't seem to be enough for long-term investors.
Key Takeaways LYB, NEXA, VIST and SHIP offer high earnings yields and meet the selection criteria.All four stocks show rising EPS estimates and projected year-over-year earnings growth in 2026.Each company has a Zacks Rank #1 and solid trading volume, indicating liquidity and upside potential. Markets are likely to remain volatile as geopolitical tensions in the Middle East show little sign of resolution. U.S. President Trump’s comments describing the ceasefire as being on “massive life support” have added to investor concerns. With hopes for a U.S.–Iran peace deal fading, uncertainty has increased, pushing oil prices higher. Brent and WTI are trading above $100 per barrel, partly due to disruptions around the Strait of Hormuz.
Rising energy costs are feeding into broader inflation. The latest CPI data showed a 0.6% increase in April, lifting annual inflation to 3.8%, slightly above expectations and the largest rise since May 2023. Sticky inflation and higher fuel prices are likely to keep markets choppy.
In such conditions, value investing becomes important, as it emphasizes strong fundamentals and long-term discipline over short-term volatility. This approach involves buying stocks that are priced below what they are really worth. It works on the idea that markets often misprice stocks, giving investors a chance to buy low and profit later.
LyondellBasell Industries N.V. (LYB - Free Report) , Nexa Resources (NEXA - Free Report) , Vista Energy (VIST - Free Report) and Seanergy Maritime Holdings Corp (SHIP - Free Report) are a few solid high-value picks with high earnings yields.
Understanding Earnings Yield MetricEarnings yield shows how much profit a company makes for each dollar of its stock price. The metric, expressed in percentage, is calculated as (Annual Earnings per Share/Market Price) x 100. It is actually the reverse of the price-to-earnings (P/E) ratio. A high earnings yield may mean the stock is undervalued. A low yield could mean the stock is too expensive.
Investors can also use earnings yield to compare stocks with bond returns like the 10-year Treasury yield. If the stock market's earnings yield is higher than the bond yield, stocks might be more attractive. With regard to this, earnings yield can be more illuminating than the traditional P/E ratio, as the former facilitates the comparison of stocks with fixed-income securities.
The Winning StrategyWe have set an Earnings Yield greater than 10% as our primary screening criterion but it alone cannot be used for picking stocks that have the potential to generate solid returns. So, we have added the following parameters to the screen:
Estimated EPS growth for the next 12 months greater than or equal to the S&P 500: This metric compares the 12-month forward EPS estimate with the 12-month actual EPS.
Average Daily Volume (20 Day) greater than or equal to 100,000: High trading volume implies that a stock has adequate liquidity.
Current Price greater than or equal to $5.
Buy-Rated Stocks: Stocks with a Zacks Rank #1 (Strong Buy) or 2 (Buy) have been known to outperform peers in any type of market environment. You can see the complete list of today’s Zacks #1 Rank stocks here.
Our PicksHere we highlight four of the 40 stocks that qualified the screening:
LyondellBasell is a global leader in plastics, chemicals, and refining. Its products serve key industries such as electronics, automotive, packaging, construction, and biofuels. The Zacks Consensus Estimate for LYB’s 2026 sales and earnings implies year-over-year growth of 12% and 414%, respectively. EPS estimates for the current and next year have moved up by 38 cents and 40 cents, respectively, over the past seven days. LyondellBasell currently sports a Zacks Rank #1 and has a Value Score of B.
Nexa Resources is an integrated zinc producer, engaged in developing and operating mining and smelting assets, primarily in Latin America. The Zacks Consensus Estimate for NEXA’s 2026 sales and earnings implies year-over-year growth of 8% and 145%, respectively. EPS estimates for the current and next year have moved up by 22 cents and 18 cents, respectively, over the past 30 days. Nexa Resources currently sports a Zacks Rank #1 and has a Value Score of A.
Vista Energy is a leading exploration and production company with a strong footprint in Vaca Muerta, which is among the largest shale oil and gas resources outside of North America. The Zacks Consensus Estimate for VIST’s 2026 sales and earnings implies year-over-year growth of 63% and 310%, respectively. EPS estimates for the current and next year have moved up by $1.58 and $1.63, respectively, over the past 30 days. Vista Energy currently sports a Zacks Rank #1 and has a Value Score of A.
Seanergy Maritime is a global shipping firm focused on transporting dry bulk commodities by sea. The Zacks Consensus Estimate for SHIP’s 2026 sales and earnings implies year-over-year growth of 16% and 63%, respectively. EPS estimates for the current and next year have moved up by 13 cents and 10 cents, respectively, over the past 30 days. Seanergy Maritime currently sports a Zacks Rank #1 and has a Value Score of B.
Key Takeaways PBI, CHRD, BTSG, MPC and LYB beat the S&P 500 across 12-, 4- and 1-week periods.Screen also demanded positive Q1 estimate revisions, $5 price, and 50k average 20-day volume.Estimates for 2026 earnings rose over 60 days; 1-year gains span 26.8-140.2%. Wall Street’s momentum remains impressive, even after a brief pause following a record-setting run. Major indexes recently touched fresh highs, showing that investors are still willing to look beyond short-term noise such as rising bond yields, elevated oil prices and ongoing geopolitical tensions. While higher-for-longer interest rates may limit near-term enthusiasm, the broader market continues to draw support from strong earnings and steady economic activity.
A major driver of this resilience has been the continued leadership of large technology companies, especially those investing aggressively in artificial intelligence. Their earnings strength and growth outlook have helped keep sentiment constructive, even as inflation and global uncertainty stay in focus. At the same time, improving confidence around global trade discussions has added another layer of support.
Markets may remain volatile, but the bigger trend still looks constructive. In this kind of environment, relative price strength stands out as a smart strategy, helping investors focus on stocks already showing leadership while broader momentum remains positive.
At this stage, investors would be wise to consider companies such as Pitney Bowes (PBI - Free Report) , Chord Energy (CHRD - Free Report) , BrightSpring Health Services (BTSG - Free Report) Marathon Petroleum (MPC - Free Report) and LyondellBasell Industries (LYB - Free Report) .
Relative Price Strength Strategy
Earnings growth and valuation multiples are indeed important for investors to determine a stock's ability to offer considerable returns. However, these are also essential for determining whether a stock’s price performance is better than its peers or the industry average.
If a stock’s performance is lacking that of the broader groups, despite impressive earnings growth or valuation multiples, then something must be wrong.
It’s always advisable to stay away from these stocks and bet on those that are outperforming their respective industry or benchmark. This is because betting on a winner always proves to be lucrative.
Then again, it is imperative that you determine whether or not an investment has relevant upside potential when considering stocks with significant relative price strength. Stocks delivering better than the S&P 500 for 1 to 3 months, at least, and having solid fundamentals, indicate room for growth and the best way to go about this strategy.
Finally, it is crucial to find out whether analysts are optimistic about the upcoming earnings of these companies. In order to do this, we have added positive estimate revisions for the current quarter’s (Q1) earnings to our screen. When a stock undergoes an upward revision, it leads to additional price gains.
Screening Parameters
Relative % Price change – 12 weeks greater than 0
Relative % Price change – 4 weeks greater than 0
Relative % Price change – 1 week greater than 0
(We have considered those stocks that have been outperforming the S&P 500 over the last 12 weeks, four weeks and one week.)
% Change (Q1) Est. over 4 Weeks greater than 0:Positive current-quarter estimate revisions over the last four weeks.
Zacks Rank equal to 1:Only Zacks Rank #1 (Strong Buy) stocks — that have returned more than 26% annually over the last 26 years and surpassed the S&P 500 in 23 of the last 26 years — can get through. You can see the complete list of today’s Zacks #1 Rank stocks here.
Current Price greater than or equal to $5 and Average 20-day Volume greater than or equal to 50,000:A minimum price of $5 is a good standard to screen low-priced stocks, while a high trading volume would imply adequate liquidity.
VGM Score less than or equal to B:Our research shows that stocks with a VGM Score of A or B, when combined with a Zacks Rank #1 or 2 (Buy), offer the best upside potential.
Here are five of the 21 stocks that made it through the screen:
Pitney Bowes:Based in Shelton, CT, Pitney Bowes helps businesses send, track, sort and receive mail and parcels through SendTech and Presort Services. Over the past 60 days, the Zacks Consensus Estimate for Pitney Bowes’ 2026 earnings has moved up 11%. The company has a VGM Score of A.
The Zacks Consensus Estimate for 2026 earnings of Pitney Bowes indicates 20% growth. It has a market capitalization of roughly 2.1 billion. PBI shares have risen 70.3% in a year.
Chord Energy:It is a Houston-based oil and gas explorer focused entirely on the Williston Basin. The Zacks Consensus Estimate for 2026 earnings of Chord Energy indicates 95.3% growth. CHRD has a VGM Score of B.
The firm has a market capitalization of around $8.4 billion. Over the past 60 days, the Zacks Consensus Estimate for Chord Energy’s 2026 earnings has gone up 173.3%. CHRD’s shares have gained 56.1% in a year.
BrightSpring Health Services:It is a national home- and community-based healthcare services platform integrating pharmacy and provider care for medically complex patients across Medicare, Medicaid and commercial payors. The Zacks Consensus Estimate for 2026 earnings of BrightSpring indicates 64% growth. BTSG has a VGM Score of B.
Over the past 60 days, the Zacks Consensus Estimate for BrightSpring’s 2026 earnings has moved up 9.3%. The company has a market capitalization of $11.2 billion. BTSG shares have gone up 140.2% in a year.
Marathon Petroleum: It is a major independent refiner, transporter and marketer of petroleum products. The Zacks Consensus Estimate for 2026 earnings of Marathon Petroleum indicates 177.3% growth. MPC has a VGM Score of A.
Over the past 60 days, the Zacks Consensus Estimate for Marathon Petroleum’s 2026 earnings has moved up 105.3%. The company has a market capitalization of $74.5 billion. MPC shares have gone up 57.1% in a year.
LyondellBasell Industries:Headquartered in London, UK, LyondellBasell Industries N.V. is among the leading plastics, chemical and refining companies globally with operations across 18 countries. The company’s expected EPS growth rate for three to five years is currently 49.4%, which compares favorably with the industry's growth rate of 17.5%. LYB has a VGM Score of B.
Over the past 60 days, the Zacks Consensus Estimate for LyondellBasell’s 2026 earnings has moved up 187.2%. The Zacks Consensus Estimate for 2026 earnings of the company indicates 413.5% growth. LYB shares have gained 26.8% in a year.
LyondellBasell (LYB - Free Report) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts still raising their earnings estimates for the company.
Analysts' growing optimism on the earnings prospects of this oil refiner and chemical company is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- is principally built on this insight.
The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.
For LyondellBasell, there has been strong agreement among the covering analysts in raising earnings estimates, which has helped push consensus estimates considerably higher for the next quarter and full year.
The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:
12 Month EPS
Current-Quarter Estimate RevisionsFor the current quarter, the company is expected to earn $2.85 per share, which is a change of +359.7% from the year-ago reported number.
Over the last 30 days, the Zacks Consensus Estimate for LyondellBasell has increased 101.56% because four estimates have moved higher compared to no negative revisions.
Current-Year Estimate RevisionsFor the full year, the earnings estimate of $8.73 per share represents a change of +413.5% from the year-ago number.
The revisions trend for the current year also appears quite promising for LyondellBasell, with seven estimates moving higher over the past month compared to no negative revisions. The consensus estimate has also received a boost over this time frame, increasing 88.81%.
Favorable Zacks RankThe promising estimate revisions have helped LyondellBasell earn a Zacks Rank #1 (Strong Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.
Bottom LineLyondellBasell shares have added 13.3% over the past four weeks, suggesting that investors are betting on its impressive estimate revisions. So, you may consider adding it to your portfolio right away to benefit from its earnings growth prospects.
HOUSTON and LONDON, May 22, 2026 (GLOBE NEWSWIRE) -- LyondellBasell (NYSE: LYB) today announced it has declared a dividend of $0.69 per share, to be paid to shareholders on June 8, 2026, with an ex-dividend and record date of June 1, 2026.
Investors interested in Chemical - Diversified stocks are likely familiar with LyondellBasell (LYB - Free Report) and Air Liquide (AIQUY - Free Report) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
LyondellBasell and Air Liquide are sporting Zacks Ranks of #1 (Strong Buy) and #2 (Buy), respectively, right now. The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that LYB has an improving earnings outlook. However, value investors will care about much more than just this.
Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.
Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.
LYB currently has a forward P/E ratio of 7.99, while AIQUY has a forward P/E of 26.26. We also note that LYB has a PEG ratio of 0.16. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. AIQUY currently has a PEG ratio of 2.94.
Another notable valuation metric for LYB is its P/B ratio of 2.24. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, AIQUY has a P/B of 3.98.
Based on these metrics and many more, LYB holds a Value grade of B, while AIQUY has a Value grade of D.
LYB is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that LYB is likely the superior value option right now.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving room for profits.
Luckily, Zacks has developed its own Style Scores system in an effort to find stocks with specific traits. Value investors will be interested in the system's "Value" category. Stocks with both "A" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now.
One company to watch right now is LyondellBasell Industries (LYB - Free Report) . LYB is currently sporting a Zacks Rank #1 (Strong Buy), as well as an A grade for Value. The stock has a Forward P/E ratio of 12.75. This compares to its industry's average Forward P/E of 13.47. Over the past year, LYB's Forward P/E has been as high as 14.89 and as low as 8.44, with a median of 11.25.
Investors should also recognize that LYB has a P/B ratio of 1.4. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. This company's current P/B looks solid when compared to its industry's average P/B of 2.08. Over the past year, LYB's P/B has been as high as 2.33 and as low as 1.30, with a median of 1.78.
Value investors also use the P/S ratio. The P/S ratio is calculated as price divided by sales. This is a popular metric because sales are harder to manipulate on an income statement, so they are often considered a better performance indicator. LYB has a P/S ratio of 0.73. This compares to its industry's average P/S of 0.76.
These are just a handful of the figures considered in LyondellBasell Industries's great Value grade. Still, they help show that the stock is likely being undervalued at the moment. Add this to the strength of its earnings outlook, and we can clearly see that LYB is an impressive value stock right now.
Investors interested in stocks from the Chemical - Diversified sector have probably already heard of LyondellBasell (LYB - Free Report) and Air Liquide (AIQUY - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
LyondellBasell has a Zacks Rank of #1 (Strong Buy), while Air Liquide has a Zacks Rank of #3 (Hold) right now. Investors should feel comfortable knowing that LYB likely has seen a stronger improvement to its earnings outlook than AIQUY has recently. But this is only part of the picture for value investors.
Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels.
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.
LYB currently has a forward P/E ratio of 7.29, while AIQUY has a forward P/E of 27.16. We also note that LYB has a PEG ratio of 0.15. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. AIQUY currently has a PEG ratio of 3.04.
Another notable valuation metric for LYB is its P/B ratio of 2.04. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, AIQUY has a P/B of 4.08.
Based on these metrics and many more, LYB holds a Value grade of A, while AIQUY has a Value grade of D.
LYB stands above AIQUY thanks to its solid earnings outlook, and based on these valuation figures, we also feel that LYB is the superior value option right now.
Note: The following is an excerpt from this week’sEarnings Trends report. You can access the full report that contains detailed historical actual and estimates for the current and following periods, please click here>>>
Here are the key points:
Total Q2 earnings for the S&P 500 index are currently expected to be up +21.8% from the same period last year on +10.9% higher revenues, with 11 of the 16 Zacks sectors expected to enjoy positive earnings growth.Q2 earnings estimates have been steadily going up since the quarter got underway, with the current +21.8% growth rate up from +18% at the start of April. Estimates have increased for 5 of the 16 Zacks sectors, including the Tech, Energy, Basic Materials, Utilities, and Business Services sectors.Q2 earnings are expected to be above the year-earlier level for 11 of the 16 Zacks sectors, with strong growth expected at the Energy (+114.0% earnings growth), Basic Materials (+47.1%), Tech (+43.6%), Utilities (+14.6%), Aerospace (+10.8%), and Industrial Products (+10.2%) sectors. The Tech sector has been a critical growth pillar since 2023 Q3 and is expected to continue playing that role in 2026 Q2, with earnings growth of +43.6%. Excluding the Tech sector’s substantial contribution, Q2 earnings growth for the rest of the S&P 500 index would be +11.4% (vs. +21.8% otherwise).The Revisions Trend Remains PositiveThe overall earnings picture continues to be of all-around strength and a steadily improving outlook. This favorable earnings backdrop is evident in the revisions trend, as seen in how expectations for 2026 Q2 have evolved in recent weeks.
Image Source: Zacks Investment Research
We should note that Q2 estimates have resumed their upward trajectory in recent days, after modestly declining in the days prior to that, even though the overall revisions trend remains positive.
The sectors enjoying positive estimate revisions since the start of April include Energy, Tech, Basic Materials, Utilities, and Business Services. Aggregate Q2 earnings estimates would still be positive since the start of the period, even without favorable revisions for the Energy sector, but aggregate estimates would be down if we exclude the increases in the Energy and Tech sector estimates.
The Tech sector has been enjoying positive estimate revisions for more than a year now, so the sector’s ongoing positive revisions trend is basically more of the same. We have discussed in this space the positive revisions that the Mag 7 group has been experiencing. The Energy sector’s improved earnings outlook is a direct result of the Iran war, as is the upgraded earnings outlook for parts of the Basic Materials sector, particularly the Chemicals industry.
Take, for example, the evolution of Q2 EPS estimates for Dow (DOW - Free Report) , LyondellBasell Industries (LYB - Free Report) , Methanex (MEOH - Free Report) , and others. For Dow and LyondellBasell, the Zacks Consensus EPS estimates for Q2 have more than doubled over the past month, while the same for Methanex has increased by more than 30%.
On the negative side, Q2 estimates have come under renewed pressure since the start of the period for the Transportation, Autos, Medical, and Consumer Discretionary sectors.
The chart below shows S&P 500 expectations for 2026 Q2 in terms of what was achieved in the preceding four periods and what is currently expected for the following three quarters.
Image Source: Zacks Investment Research
The chart below shows the overall earnings picture for the S&P 500 index on an annual basis.
Image Source: Zacks Investment Research
As with estimates for Q2, estimates for full-year 2026 have also been steadily going up, particularly since the start of March. The chart below shows the evolution of aggregate S&P 500 earnings estimates since last July.
Image Source: Zacks Investment Research
Full-year 2026 earnings estimates have increased for 11 of the 16 Zacks sectors since the start of March, with the most pronounced gains at the Energy, Basic Materials, Tech, Industrials, Utilities, and Business Services sectors. On the negative side, estimates have been under pressure for the Transportation, Autos, Medical, and Consumer Discretionary sectors since the start of March.
LyondellBasell receives a cautious Buy at $65, reflecting leaner operations but persistent margin and China-related risks. Cost-cutting, asset sales, and a halved dividend have strengthened LYB's balance sheet, yet earnings remain subdued and net debt/EBITDA is elevated at 4.0x. PE/PP margin recovery is key; China's capacity expansion and exports cap upside, while U.S. feedstock advantage offers some support.
AbbVie is a dividend growth stock offering investors the right mix of value, growth, and yield. The pharmaceutical company inherited Dividend King status from its former parent, and the company is maintaining its strong dividend track record.
Data being presented, including six oral presentations, reinforce AbbVie's leadership and commitment to ongoing research to improve outcomes for people living with blood cancers , /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will share new data at the European Hematology Association (EHA) 2026 Congress and will showcase clinical advancements from research programs across multiple blood cancers, including multiple myeloma (MM), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML) and amyloidosis (AL). Featured data from AbbVie's blood cancer portfolio and pipeline include 21 oral and poster presentations, highlighting the investigational compound etentamig (ABBV-383), and approved therapies, EPKINLY® (epcoritamab-bysp) (TEPKINLY® in the EU), VENCLEXTA® (venetoclax) (VENCLYXTO® in the EU) and DECNUPAZ™ (pivekimab sunirine-pvzy).
"The compelling data we are presenting at EHA reflect AbbVie's robust portfolio and pipeline and our ongoing work to advance the treatment and understanding of hematologic cancers," said Daejin Abidoye, M.D., vice president, therapeutic area head, oncology, solid tumor and hematology, AbbVie. "With this research, we continue our commitment to pioneering innovative solutions that have the potential to elevate standards of care for patients and help address the most pressing challenges in treating blood cancers."
Key oral presentations of epcoritamab data include:
Treatment impact of epcoritamab with lenalidomide and rituximab in relapsed or refractory (R/R) FL A subgroup analysis of the Phase 3 EPCORE FL-1 trial (NCT05409066) of fixed-duration epcoritamab, in combination with rituximab plus lenalidomide (E+R2) for patients with R/R FL (n=243), was performed to determine if the efficacy benefit and tolerability of E+R2 extended across clinically relevant subgroups, including patients with higher- and lower-risk disease features, compared to R2.1 Between Follicular Lymphoma International Prognostic Index (FLIPI) subgroups, overall response rate (ORR) was numerically higher with E+R2 compared to R2 (FLIPI 0–2, 96.5% vs 84.8%; FLIPI 3–5, 93.0% vs 72.6%).1 A similar trend was seen in those with progression of disease less than or equal to two years from the date of initial frontline therapy (POD24).1 Across the age subgroups, ORR and complete response rates (CRR) for E+R2 and R2 for ≥65 were (94.3% vs 80.2% and 80.7% vs 44.3%, respectively) and <65 (95.5% vs 78.4% and 83.9% vs 54.0%, respectively). Progression-free survival (PFS) hazard ratios (HRs) (95% CIs) for E+R2 and R2 for the NHL-5 low co-morbidity index score were (0.27 [0.17–0.42]) and NHL-5 high + intermediate were (0.14 [0.06–0.29]).1 The E+R2 safety profile across all subgroups was consistent with the overall trial population, with no new safety signals.1 Efficacy data of epcoritamab following systemic therapy in R/R large B-cell lymphoma (LBCL) EPCORE DLBCL-1 (EudraCT No. 2020-003016-27) is a randomized Phase 3 trial in R/R LBCL evaluating epcoritamab, a CD3×CD20 bispecific antibody, monotherapy. The study showed a statistically significant improvement in PFS versus investigator's choice of chemoimmunotherapy (CIT) — either rituximab plus gemcitabine plus oxaliplatin or bendamustine plus rituximab (HR 0.74 [95% CI, 0.60–0.92]; P=0.0059; 24-month PFS: 30% vs 13%). The study did not demonstrate a statistically significant improvement in overall survival (OS) (HR: 0.96 [95% CI, 0.77–1.20]). There was no OS detriment per pre-specified criteria.*2 Epcoritamab reported a CRR of 38% and CIT 26%; (nominal P value 0.0032), duration of response (DOR) (median DOR 37 vs 6 months; duration of complete response (DOCR) NR vs 11 months, respectively) and time to next treatment (TTNT) (7 vs 4 months, respectively; nominal P value <0.0001).2 Higher rates of grade 3–4 infections (30% vs 12%) and any-grade COVID-19 (36% vs 11%) were reported in the epcoritamab arm. Grade 5 treatment-emergent adverse events (TEAEs) occurred in 17% vs 6% (exposure-adjusted, 1.5 vs 1.8 per 100 pt-mo) and were largely attributable to grade 5 COVID-19 (9% vs 2%).2 *OUS the protocol and SAP were amended to include dual primary endpoints of OS and PFS
The following studies featuring venetoclax, etentamig and pivekimab sunirine-pvzy data will also be shared as oral and poster presentations:
Predicted efficacy of venetoclax-based therapies in CLL based on genetic biomarkers Results from the Phase 3 GAIA/CLL13 (NCT02950051) trial evaluating fixed-duration venetoclax-based combinations (with rituximab, obinutuzumab and obinutuzumab plus ibrutinib) as a chemotherapy-free alternative to chemoimmunotherapy (fludarabine, cyclophosphamide and rituximab or bendamustine and rituximab) in fit, previously untreated CLL patients lacking del(17p) or TP53 mutations.3 Venetoclax in combination with rituximab and obinutuzumab plus ibrutinib in previously untreated CLL patients lacking del(17p) or TP53 mutations are investigational combinations not approved in the EU. Efficacy and safety data of venetoclax-obinutuzumab combination in previously untreated CLL Results from the open-label Phase 3 CLL14 trial (NCT02242942) comparing the efficacy and safety of venetoclax in combination with obinutuzumab to obinutuzumab plus chlorambucil in previously untreated patients with CLL and coexisting medical conditions.4 Real-world management practices with venetoclax-based therapy for AML Results from the prospective observational study, REVIVE (NCT03987958), examining the effect of antimicrobial prophylaxis, post-remission administration of G-CSF and treatment initiation setting on safety and effectiveness outcomes with venetoclax plus hypomethylating agents (HMA) in newly diagnosed AML patients unfit for intensive chemotherapy.5 Etentamig in patients with relapsed/refractory multiple myeloma (RRMM) with prior exposure to B-cell maturation antigen (BCMA)-targeted therapy Results from Arm B of the MONVISO study (NCT05650632), evaluating a flat dose of etentamig in patients with RRMM with at least two prior lines of therapy, including triple-class and prior BCMA exposure. The Phase 1b study is assessing dose optimization and safety.6 Etentamig is an investigational therapy not approved in the EU. Longer term safety and efficacy data of etentamig monotherapy in R/R light chain amyloidosis Updated results from M24-209 (NCT06158854), evaluating etentamig monotherapy in BCMA-targeted therapy-naïve patients with relapsed/refractory immunoglobulin light chain amyloidosis. The open-label Phase 1/2 study is assessing dose escalation safety and efficacy.7 Etentamig is an investigational therapy not approved in the EU. Efficacy data of pivekimab sunirine-pvzy in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) with baseline skin involvement in the CADENZA study Post-hoc analysis from CADENZA (NCT03386513), evaluating the first-line use of pivekimab sunirine-pvzy in patients with BPDCN and varying degrees of skin involvement. The open-label Phase 1/2 study is assessing overall response rate, overall survival and percentage of eligible patients approved to proceed with a stem cell transplant.8 Pivekimab sunirine-pvzy is an investigational therapy not approved in the EU. Details on key oral and poster presentations at the EHA 2026 Congress are available below and the full abstracts are available here.
Oral Presentations:
Title
Date/Time
Session
Abstract/ Presentation Number
Clinically Relevant Subgroup Analysis from the Randomized Phase 3 EPCORE FL-1 Trial: Treatment (Tx) Effect of Epcoritamab with Lenalidomide and Rituximab (R2) in R/R Follicular Lymphoma (FL)
Thursday, June 11,
17:45 - 18:00 CEST
Oral Session,
K1 Hall
EHA-3041
Short: S229
Results from EPCORE DLBCL-1: Randomized Phase 3 Study of Epcoritamab (Epcor) Vs Investigator's Choice Chemoimmunotherapy (CIT) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL)
Friday, June 12,
17:15 - 17:30 CEST
Oral Session,
Nobel Hall
EHA-2409
Short: S235
Venetoclax-obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia: Final Results of the Randomized CLL14 Study
Friday, June 12,
17:30 - 17:45 CEST
Oral Session,
AE1 Hall
EHA-2488
Short: S146
Genetic Biomarkers Predicting Sustained Efficacy of Venetoclax-based Therapies or CIT in Chronic Lymphocytic Leukemia: Final 5-year Analysis of the GAIA/CLL13 Trial
Friday, June 12,
18:15 - 18:30 CEST
Oral Session,
AE1 Hall
EHA-4841
Short: S149
Phase 1 Dose Escalation Safety and Efficacy of Etentamig in Patients with Relapsed or Refractory Light Chain Amyloidosis
Friday, June 12,
18:15 - 18:30 CEST
Oral Session,
Victoria Hall
EHA-1134
Short: S209
Fixed Duration Venetoclax Plus Epcoritamab Shows Favorable Tolerability and High Response Rates with Early Molecular Responses in R/R CLL/SLL: Interim Analysis of the Randomized HOVON 165/AETHER Trial
Sunday, June 14,
11:45 - 12:00 CEST
Oral Session,
A10-11 Hall
EHA-3784
Short: S153
Poster Presentations:
Sustained Remissions Beyond 4 Years with Epcoritamab Monotherapy: Long-term Follow-up Results from the Pivotal EPCORE NHL-1 Trial in Patients with Relapsed or Refractory Large B-cell Lymphoma
Friday, June 12,
18:45 CEST
Poster Session, Hall A
EHA-2191
Short: PF977
Epcoritamab + R-mini-chop Results In 2-year Remissions and High MRD-negativity Rates in Elderly Patients with Newly Diagnosed DLBCL: Results from the EPCORE NHL-2 Trial
Friday, June 12,
18:45 CEST
Poster Session,
Hall A
EHA-2359
Short: PF1007
Reduced CD20 Expression and Intratumoral CD3+ T Cells Following Epcoritamab Treatment Are Associated with Progressive Disease in a Subset of Diffuse Large B-cell Lymphoma and Follicular Lymphoma
Friday, June 12,
18:45 CEST
Poster Session, Hall A
EHA-2343
Short: PF1069
Pharmacodynamic Biomarkers Support the Clinical Benefit of Epcoritamab Plus Rituximab and Lenalidomide (R2) In Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL): Analyses from EPCORE FL-1
Friday, June 12,
18:45 CEST
Poster Session, Hall A
EHA-3123
Short: PF1081
Real-world Management Practices with Venetoclax-based Therapy For AML - Results from the Prospective REVIVE Study
Friday, June 12,
18:45 CEST
Poster Session,
Hall A
EHA-3291
Short: PF536
The Efficacy of Pivekimab Sunirine (PVEK) in Patients (PTS) with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) with Baseline Skin Involvement in the CADENZA Study
Friday, June 12,
18:45 CEST
Poster Session,
Hall A
EHA-1950
Short: PF500
Anchored Matching-adjusted Indirect Comparison of Epcoritamab, Lenalidomide, and Rituximab Vs Tafasitamab, Lenalidomide, and Rituximab in Relapsed/Refractory Follicular Lymphoma: EPCORE FL-1 Vs Inmind
Saturday, June 13,
18:45 CEST
Poster Session, Hall A
EHA-1124
Short: PS2035
Comparative Effectiveness of Epcoritamab, Lenalidomide, and Rituximab in EPCORE FL-1 Vs Real-world Chemoimmunotherapy in Relapsed/Refractory Follicular Lymphoma
Saturday, June 13,
18:45 CEST
Poster Session, Hall A
EHA-3065
Short: PS2042
Comparative Analyses of Epcoritamab in Combination with Lenalidomide and Rituximab Vs Obinutuzumab and Bendamustine in Relapsed/Refractory Follicular Lymphoma
Saturday, June 13,
18:45 CEST
Poster Session, Hall A
EHA-3140
Short: PS2052
Epcoritamab + Chemoimmunotherapy in Patients with Relapsed/Refractory Large B-cell Lymphoma Eligible for Autologous Stem Cell Transplant: Pooled Results from Arms 4 and 10 of EPCORE NHL-2
Saturday, June 13,
18:45 CEST
Poster Session,
Hall A
EHA-2303
Short: PS2070
Fixed-duration Epcoritamab Monotherapy Induces High Response and MRD-negativity Rates in Elderly Patients with Newly Diagnosed Large B-cell Lymphoma and Comorbidities: Results from EPCORE DLBCL-3
Saturday, June 13,
18:45 CEST
Poster Session, Hall A
EHA-2346
Short: PS2082
Epcoritamab In Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL): Insights from the Real-world Epcoritamab Patient Characteristics and Outcomes Research (Real-epcor) Study
Saturday, June 13,
18:45 CEST
Poster Session, Hall A
EHA-2202
Short: PS2086
Epcoritamab Plus Lenalidomide and Rituximab Improves or Preserves Health-related Quality of Life in Patients with Relapsed/Refractory Follicular Lymphoma Who Had High Symptom Burden or Adverse Events
Saturday, June 13,
18:45 CEST
Poster Session, Hall A
EHA-2776
Short: PS2497
Quality of Life and Symptoms with Fixed-duration Acalabrutinib + Venetoclax ± Obinutuzumab Vs Chemoimmunotherapy in Treatment-naive Chronic Lymphocytic Leukemia: Patient-Reported Outcomes from AMPLIFY
Saturday, June 13,
18:45 CEST
Poster Session,
Hall A
EHA-4662
Short: PS1706
Etentamig In Patients (PTS) with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to B-cell Maturation Antigen (BCMA)-targeted Therapy
Saturday, June 13,
18:45 CEST
Poster Session,
Hall A
EHA-2799
Short: PS1913
Etentamig (ABBV-383) is an investigational medicine and is not approved by any health authorities worldwide. The safety and efficacy of this medicine is under evaluation as part of ongoing clinical studies. Pivekimab sunirine is not approved in the EU.
EPKINLY®/TEPKINLY® (epcoritamab) and VENCLEXTA®/VENCLYXTO® (venetoclax) are approved medicines being investigated for additional uses. Safety and efficacy have not been established for these unapproved additional uses.
EPKINLY®/TEPKINLY® (epcoritamab) is being co-developed by Genmab and AbbVie as part of the companies' oncology collaboration. The companies share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization.
VENCLEXTA®/VENCLYXTO® (venetoclax) is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S.
Additional information on AbbVie clinical trials is available at https://www.clinicaltrials.gov/.
USE & IMPORTANT SAFETY INFORMATION for EPKINLY® (epcoritamab-bysp) in U.S.
What is EPKINLY?
EPKINLY is a prescription medicine used to treat adults with:
certain types of diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma that has come back (relapsed) or that did not respond (refractory) after 2 or more treatments. follicular lymphoma (FL) that has come back or that did not respond to previous treatment, together with lenalidomide and rituximab follicular lymphoma (FL) that has come back or that did not respond after 2 or more treatments. EPKINLY for the treatment of DLBCL is approved based on patient response data. Studies are ongoing to confirm the clinical benefit of EPKINLY.
It is not known if EPKINLY is safe and effective in children.
IMPORTANT SAFETY INFORMATION
Important Warnings—EPKINLY can cause serious side effects, including:
Cytokine release syndrome (CRS), which is common during treatment with EPKINLY and can be serious or lead to death. To help reduce your risk of CRS, you will receive EPKINLY on a step-up dosing schedule (when you receive 2 or 3 smaller step-up doses of EPKINLY before your first full dose during your first cycle of treatment), and you may also receive other medicines before and for 3 days after receiving EPKINLY. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule. Neurologic problems that can be serious, and can be life-threatening, and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY. People with DLBCL or high-grade B-cell lymphoma may be hospitalized after receiving their first full dose of EPKINLY on Day 15 of Cycle 1 due to the risk of CRS and neurologic problems.
People with FL may be hospitalized after receiving their first full dose of EPKINLY on Day 22 of Cycle 1 due to the risk of CRS and neurologic problems.
Tell your healthcare provider or get medical help right away if you develop a fever of 100.4°F (38°C) or higher; dizziness or lightheadedness; trouble breathing; chills; fast heartbeat; feeling anxious; headache; confusion; shaking (tremors); problems with balance and movement, such as trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. These may be symptoms of CRS or neurologic problems. If you have any symptoms that impair consciousness, do not drive or use heavy machinery or do other dangerous activities until your symptoms go away.
EPKINLY can cause other serious side effects, including:
Infections that may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment and treat you as needed if you develop an infection. You should receive medicines from your healthcare provider before you start treatment to help prevent infection. Tell your healthcare provider right away if you develop any symptoms of infection during treatment, including fever of 100.4°F (38°C) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, feeling weak or generally unwell, or confusion. Low blood cell counts, which can be serious or severe. Your healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including low white blood cells (neutropenia and lymphopenia), which can increase your risk for infection; low red blood cells (anemia), which can cause tiredness and shortness of breath; and low platelets (thrombocytopenia), which can cause bruising or bleeding problems. Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects.
Before you receive EPKINLY, tell your healthcare provider about all your medical conditions, including if you have an infection, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. If you receive EPKINLY while pregnant, it may harm your unborn baby. If you are a female who can become pregnant, your healthcare provider should do a pregnancy test before you start treatment with EPKINLY and you should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY. Do not breastfeed during treatment with EPKINLY and for 4 months after your last dose of EPKINLY.
The most common side effects of EPKINLY when used alone in DLBCL or high-grade B-cell lymphoma or FL include CRS, injection site reactions, tiredness, muscle and bone pain, fever, diarrhea, COVID-19, rash, and stomach-area (abdominal) pain. The most common severe abnormal laboratory test results with EPKINLY when used alone include decreased white blood cells, decreased red blood cells, and decreased platelets.
The most common side effects of EPKINLY when used together with lenalidomide and rituximab in FL include rash, upper respiratory tract infections, tiredness, injection site reactions, constipation, diarrhea, CRS, pneumonia, COVID-19, and fever. The most common severe abnormal laboratory test results with EPKINLY when used together with lenalidomide and rituximab include decreased white blood cells and decreased platelets.
These are not all of the possible side effects of EPKINLY. Call your doctor for medical advice about side effects.
You are encouraged to report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to Genmab US, Inc. at 1-855-4GENMAB (1-855-443-6622).
Please see Full Prescribing Information and Medication Guide, including Important Warnings.
Globally, prescribing information varies. Refer to the individual country product label for complete information.
USE & IMPORTANT SAFETY INFORMATION for VENCLEXTA® (venetoclax tablets) in U.S.
Uses
VENCLEXTA is a prescription medicine used:
to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). in combination with azacitidine, or decitabine, or low-dose cytarabine to treat adults with newly diagnosed acute myeloid leukemia (AML) who:
‒ are 75 years of age or older, or
‒ have other medical conditions that prevent the use of standard chemotherapy. It is not known if VENCLEXTA is safe and effective in children.
Important Safety Information
What is the most important information I should know about VENCLEXTA?
VENCLEXTA can cause serious side effects, including:
Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure, the need for dialysis treatment, and may lead to death. Your healthcare provider will do tests to check your risk of getting TLS before you start taking VENCLEXTA. You will receive other medicines before starting and during treatment with VENCLEXTA to help reduce your risk of TLS. You may also need to receive intravenous (IV) fluids into your vein. Your healthcare provider will do blood tests to check for TLS when you first start and during treatment with VENCLEXTA. It is important to keep your appointments for blood tests. Tell your healthcare provider right away if you get any symptoms of TLS during treatment with VENCLEXTA, including fever, chills, nausea, vomiting, confusion, shortness of breath, seizures, irregular heartbeat, dark or cloudy urine, unusual tiredness, or muscle or joint pain.
Drink plenty of water during treatment with VENCLEXTA to help reduce your risk of getting TLS. Drink 6 to 8 glasses (about 56 ounces total) of water each day, starting 2 days before your first dose, on the day of your first dose of VENCLEXTA, and each time your dose is increased.
Your healthcare provider may delay, decrease your dose, or stop treatment with VENCLEXTA if you get symptoms of TLS. When restarting VENCLEXTA after stopping for 1 week or longer, your healthcare provider may check again for your risk of TLS and change your dose.
Who should not take VENCLEXTA?
Patients taking certain medicines during the beginning of VENCLEXTA (when the dose is being slowly increased) are at increased risk of TLS.
Tell your healthcare provider about all the medicines you take, including prescription and over-the- counter medicines, vitamins, and herbal supplements. VENCLEXTA and other medicines may affect each other causing serious side effects. Do not start new medicines during treatment with VENCLEXTA without first talking with your healthcare provider. Before taking VENCLEXTA, tell your healthcare provider about all of your medical conditions, including if you:
have kidney or liver problems. have problems with your body salts or electrolytes, such as potassium, phosphorus, or calcium. have a history of high uric acid levels in your blood or gout. are scheduled to receive a vaccine. You should not receive a "live vaccine" before, during, or after treatment with VENCLEXTA, until your healthcare provider tells you it is okay. If you are not sure about the type of immunization or vaccine, ask your healthcare provider. These vaccines may not be safe or may not work as well during treatment with VENCLEXTA. are pregnant or plan to become pregnant. VENCLEXTA may harm your unborn baby.
Females who are able to become pregnant:
‒ Your healthcare provider should do a pregnancy test before you start treatment with VENCLEXTA.
‒ Use effective birth control during treatment and for 30 days after the last dose of VENCLEXTA.
‒ If you become pregnant or think you are pregnant, tell your healthcare provider right away. are breastfeeding or plan to breastfeed. It is not known if VENCLEXTA passes into your breast milk. Do not breastfeed during treatment with VENCLEXTA and for 1 week after the last dose. What should I avoid while taking VENCLEXTA?
You should not drink grapefruit juice or eat grapefruit, Seville oranges (often used in marmalades), or starfruit during treatment with VENCLEXTA. These products may increase the amount of VENCLEXTA in your blood.
What are the possible side effects of VENCLEXTA?
VENCLEXTA can cause serious side effects, including:
Low white blood cell counts (neutropenia). Your healthcare provider will do blood tests to check your blood count during treatment with VENCLEXTA and may pause dosing of VENCLEXTA or give you medicines to help treat your neutropenia if it is severe. Infections. Death and serious infections such as pneumonia and blood infection (sepsis) have happened during treatment with VENCLEXTA. Your healthcare provider will closely monitor and treat you right away if you get a fever or any signs of infection during treatment with VENCLEXTA. Tell your healthcare provider right away if you get a fever or any signs of an infection during treatment with VENCLEXTA.
The most common side effects of VENCLEXTA when used in combination with acalabrutinib in people with CLL or SLL include low white blood cell count, headache, diarrhea, muscle and bone pain, and COVID-19.
The most common side effects of VENCLEXTA when used in combination with obinutuzumab or rituximab or alone in people with CLL or SLL include low white blood cell count; low platelet count; low red blood cell count; diarrhea; nausea; upper respiratory tract infection; cough; muscle and joint pain; tiredness; and swelling of your arms, legs, hands, and feet.
The most common side effects of VENCLEXTA in combination with azacitidine or decitabine or low-dose cytarabine in people with AML include nausea; diarrhea; low platelet count; constipation; low white blood cell count; fever with low white blood cell count; tiredness; vomiting; swelling of arms, legs, hands, or feet; fever; infection in lungs; shortness of breath; bleeding; low red blood cell count; rash; stomach (abdominal) pain; infection in your blood; muscle and joint pain; dizziness; cough; sore throat; and low blood pressure.
Your healthcare provider may temporarily stop VENCLEXTA treatment, decrease your dose, or completely stop treatment if you get severe side effects.
VENCLEXTA may cause fertility problems in males. This may affect your ability to father a child. Talk to your healthcare provider if you have concerns about fertility.
These are not all the possible side effects of VENCLEXTA. Call your doctor for medical advice about side effects.
You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
If you cannot afford your medication, contact genentech-access.com/patient/brands/venclexta for assistance.
Please see full Prescribing Information. Globally, prescribing information varies. Refer to the individual country product label for complete information.
U.S. Prescribing Information for AbbVie Medicines
Please see full Prescribing Information including BOXED WARNING for DECNUPAZ (pivekimab sunirine-pvzy)
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
About AbbVie in Oncology
AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.
Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Contacts:
_________________________________
1
Tessoulin B, Nijland M, et al. Clinically Relevant Subgroup Analysis From The Randomized Phase 3 EPCORE FL-1 Trial: Treatment (Tx) Effect Of Epcoritamab With Lenalidomide And Rituximab (R²) In R/R Follicular Lymphoma (Fl). Abstract EHA-3041 presented at the European Hematology Association Congress 2026. Stockholm, Sweden.
2
Fox C, Inchiappa L, et al. Results From EPCORE DLBCL-1: Randomized Phase 3 Study Of Epcoritamab (Epcor) Vs Investigator's Choice Chemoimmunotherapy (Cit) In Patients With Relapsed/Refractory Large B-Cell Lymphoma (R/R Lbcl). Abstract EHA-2409 presented at the European Hematology Association Congress 2026. Stockholm, Sweden.
3
Tausch E, Schneider C, et al. Genetic Biomarkers Predicting Sustained Efficacy of Venetoclax-based Therapies or CIT in Chronic Lymphocytic Leukemia: Final 5-yr Analysis of the GAIA/CLL13 Trial. Abstract EHA-4841 presented at the European Hematology Association Congress 2026. Stockholm, Sweden.
4
Fischer K, Al-Sawaf O ,et al. Venetoclax-obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia: Final Results of the Randomized CLL14 Study. Abstract EHA-2488 presented at the European Hematology Association Congress 2026. Stockholm, Sweden.
5
Moshe Y, Wolach O, et al. Real-world Management Practices with Venetoclax-based Therapy For AML- Results from the Prospective REVIVE Study. Abstract EHA- 3291 presented at the European Hematology Association Congress 2026. Stockholm, Sweden.
6
Chhabra S, Searle E, et al. Etentamig In Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to B-cell Maturation Antigen (BCMA)-targeted Therapy. Abstract EHA-2799 presented at the European Hematology Association Congress 2026. Stockholm, Sweden.
7
Kastritis E, Huart A, et al. Phase 1 Dose Escalation Safety and Efficacy of Etentamig in Patients with Relapsed or Refractory Light Chain Amyloidosis. Abstract EHA-1134 presented at the European Hematology Association Congress 2026. Stockholm, Sweden.
8
Pemmaraju N, Marconi G, et al. Efficacy of pivekimab sunirine-pvzy in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) with baseline skin involvement in the CADENZA study Abstract EHA-1950 presented at the European Hematology Association Congress 2026. Stockholm, Sweden.
A retiree's $40,000 dividend income stream sounds modest next to a neighbor's $90,000. But the growth rate often matters more than the starting number. A portfolio generating $40,000 today that grows its income by 8% annually produces roughly $86,000 in ten years and more than $186,000 in twenty. That is the power of compounding. The... The Dividend Growth Portfolio That Starts at $40,000 a Year and Ends at $150,000
Key Takeaways Healthcare is benefiting from demand for GLP-1 drugs and the growing use of AI in drug discovery.Eli Lilly reached a 52-week high amid expanded AI efforts through a partnership with NVIDIA.ETFs like IHE offer healthcare exposure with significant holdings in Eli Lilly and other pharma firms. The global geopolitical landscape has plunged into a deep state of uncertainty once again following a direct exchange of missile strikes between Iran and Israel over the weekend. Although a fragile, temporary ceasefire was announced yesterday, history suggests there is no guarantee that hostilities will not resume at a moment’s notice in the Middle East.
This volatility may lead investors to rotate away from the highly volatile Silicon Valley investments, as they did last Friday. The sell-off was driven by a dual catalyst — a stronger-than-expected May U.S. jobs report, which reignited concerns that the Federal Reserve may keep interest rates higher for longer, and growing institutional anxiety over AI concentration risk and elevated valuations.
Such volatile situations tend to force risk-averse market participants to increase their positions in defensive safe havens like healthcare stocks and, by extension, healthcare exchange-traded funds (ETFs), which boast inelastic demand.
Before identifying those ETFs for your portfolio, a strategic investor must look past the immediate headlines. Examining the fundamental factors currently accelerating the healthcare sector, the primary players driving the sector’s rally, and assessing its future ensures that shielding your capital from global friction is an investment driven by hard data rather than reactionary panic.
Factors Fueling Healthcare & Major PlayersThe fundamental factors driving the healthcare sector’s recent expansion extend far beyond simple defensive positioning. The sector has been particularly flourishing of late due to two explosive factors: blockbuster weight-loss drugs and AI-driven drug discovery.
Leading the charge in the healthcare space is undoubtedly Eli Lilly (LLY - Free Report) , which has defied broader market volatility to touch a new record 52-week high of $1,166 per share on June 5, 2026. Eli Lilly now controls roughly 60% of the booming GLP-1 weight-loss and diabetes market. It generated $13 billion in revenues in the first quarter of 2026, driven by LLY’s GLP-1 blockbuster drugs, Mounjaro and Zepbound, putting the company on an annualized run rate of more than $50 billion for its diabetes and weight-loss franchise. Meanwhile, recently released clinical trial data for its oral weight-loss drug, Foundayo, could further accelerate the franchise’s growth momentum.
The company is also rapidly scaling its AI drug discovery capabilities, heavily investing in advanced computing infrastructure and high-value partnerships to accelerate preclinical development. In January 2026, LLY joined forces with tech giant NVIDIA (NVDA - Free Report) to co-invest up to $1 billion over five years in talent, infrastructure, and computing resources to support a new AI co-innovation lab aimed at accelerating and scaling drug discovery and manufacturing.
Similar to Eli Lily, Danish drugmaker Novo Nordisk (NVO - Free Report) is another major player accelerating the growth of the healthcare sector. Alongside Eli Lily, NVO commands a lion’s share of the U.S. weight loss market and has been aggressively launching its weight-loss drugs across Europe, Asia and Latin America.
In December 2025, the U.S. Food and Drug Administration (FDA) approved Novo Nordisk’s oral obesity pill, Wegovy, making it the first GLP-1 tablet specifically cleared for chronic weight management. The company is also making its stride in AI-led drug discovery.
NVO entered into a strategic collaboration with OpenAI this April to integrate advanced AI capabilities across its value chain, from early-stage drug discovery to commercial operations. The partnership aims at accelerating the development and delivery of new therapies while enhancing operational efficiency through AI-driven insights and automation.
Outlook for Global Healthcare in the AI EraIn the era of AI, the global healthcare sector outlook is transformative. AI is no longer a Silicon Valley monopoly; it is slashing drug development timelines from years to months.
Agencies and healthcare groups are aggressively deploying agentic AI and multi-agent workflows to compress drug discovery timelines from years to months and automate clinical workflows. This structural evolution guarantees that healthcare is no longer just a slow-moving utility sector, but a hotbed of technological innovation.
To this end, a PWC report projects the global healthcare market to witness a 5% CAGR from 2025 to 2030, approaching nearly US$ 30 trillion, with the AI healthcare sub-industry estimated to reach $868 billion, yielding $222 billion in revenue gains.
Given this strong growth potential, geopolitical uncertainty stemming from the recurring tensions between Iran and Israel is likely to keep risk-averse investors on the defensive, prompting them to seek refuge in the healthcare sector's stable, recession-resilient cash flows.
Health ETFs to BuyFor those looking to capitalize on the healthcare sector’s growth momentum, as mentioned above, without facing the regulatory or clinical trial risks of individual stock picks, the following healthcare ETFs represent the best investment vehicles:
State Street Health Care Select Sector SPDR ETF (XLV - Free Report)
This fund, with assets under management (AUM) worth $39.24 billion, offers exposure to 60 companies in the pharmaceuticals; health care equipment and supplies; health care providers and services; biotechnology; life sciences tools and services; and health care technology industries. LLY holds the first spot in this fund, with 16.21% weightage.
Pharma giants, Johnson & Johnson (JNJ - Free Report) holds the second position in this fund, with 10.15% weightage, while AbbVie (ABBV - Free Report) holds the third spot with 7.26% weightage.
XLV has soared 12.5% over the past year. The fund charges 8 basis points (bps) as fees. It sports a Zacks ETF Rank #1 (Strong Buy) and traded at a good volume of 20.71 million shares in the last trading session.
Vanguard Health Care Index Fund ETF Shares (VHT - Free Report)
With net assets of $16.6 billion, this fund provides exposure to 405 companies engaged in the manufacture of healthcare equipment and supplies, the provision of healthcare-related services, and the research, development, production, and marketing of pharmaceutical and biotechnology products. LLY is the fund’s largest holding, accounting for 12.13% of assets, followed by JNJ at 8.82% and ABBV at 6.03%.
VHT has rallied 13.3% over the past year. The fund charges 9 bps as fees. It sports a Zacks ETF Rank #1 and traded at a volume of 0.41 million shares in the last trading session.
iShares U.S. Pharmaceuticals ETF (IHE - Free Report)
This fund, with net assets worth $921.5 million, offers exposure to 55 U.S. drug manufacturers and vaccine producers. LLY holds the first spot in this fund, with 24.52% weightage. JNJ holds the second position in this fund, with 20.75% weightage, while Royalty Pharma holds the third spot with 5.18% weightage.
IHE has surged 36.7% over the past year. The fund charges 38 bps as fees. It holds a Zacks ETF Rank #2 (Buy) and traded at a volume of 0.10 million shares in the last trading session.
The agency’s letter cited manufacturing-related items and raised no safety or efficacy concerns. Werschler, a Spokane dermatologist who has served as a clinical trial investigator in dermatology and aesthetic medicine, explains how a Complete Response Letter functions and what a serotype E toxin could add to the category.
SPOKANE, Wash., June 10, 2026 (GLOBE NEWSWIRE) -- AbbVie has received a Complete Response Letter from the U.S. Food and Drug Administration regarding its Biologics License Application for trenibotulinumtoxinE, known as TrenibotE, an investigational botulinum neurotoxin serotype E under review for the treatment of moderate to severe glabellar lines. According to AbbVie’s announcement, the agency’s feedback focused on manufacturing-process information and did not cite concerns related to clinical safety or efficacy. The company has said the letter did not request additional clinical trials and that it intends to submit a response in the coming months
Wm. Philip “Phil” Werschler, MD, a board-certified dermatologist in Spokane, Washington, served as a clinical trial investigator within the trenibotulinumtoxinE program. Asked about the FDA news, he kept his comments to how the regulatory process works rather than on any specific product.
“A Complete Response Letter is the formal way the FDA tells a sponsor what an application still needs before it can be approved. When the items raised concern manufacturing and chemistry rather than safety or efficacy, that is a different category of question. It speaks to process, not to the underlying clinical evidence.”
HOW A COMPLETE RESPONSE LETTER FITS THE APPROVAL PATH
Drug and device development is long and selective. The FDA’s published description of the clinical research process notes that moving a compound from discovery to patient availability commonly takes a decade or more, and longstanding industry analyses hold that only a minority of compounds entering clinical testing ever reach the market. A Complete Response Letter does not end that path. A sponsor can address the agency’s questions and resubmit, which allows the FDA to resume its review rather than start over.
“The public often reads any FDA letter as a rejection. Usually it is not. It is a list of what remains. When that list is focused on manufacturing, the work that follows is process work, and it happens routinely in this field.”
WHAT A SEROTYPE E TOXIN COULD ADD TO THE CATEGORY
Most neuromodulators in clinical use today are based on botulinum toxin type A, the family behind the products patients recognize from more than two decades of cosmetic use. A serotype E toxin behaves differently. Published descriptions of TrenibotE characterize it as having a rapid onset, with effect reported as early as eight hours after administration, and a short duration of roughly two to three weeks. That fast-onset, short-duration profile is distinct from the type A products that have defined the category.
“In practice, I hear from patients who are curious about a neuromodulator but cautious about committing to several months of effect. A category with a shorter, faster-resolving profile speaks to that hesitation. Whether any individual product earns approval is for the FDA to determine, but shorter-acting toxins are a genuinely interesting direction for the field.”
ABOUT DR. PHILIP WERSCHLER
Wm. Philip Werschler, MD, is a board-certified dermatologist practicing in Spokane, Washington. He founded Premier Clinical Research and BreakAway Research and has served as a clinical trial investigator across dermatology and aesthetic medicine, including investigative work on Botox Cosmetic, which received FDA approval for aesthetic use in 2002. He has served as Editor-in-Chief of Cosmetic Dermatology and as founding aesthetic editor of the Journal of Clinical and Aesthetic Dermatology, and he is a fellow of the American Society for Dermatologic Surgery. More information is available at spokanederm.com.
ABOUT ABBVIE
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. It strives to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in its Allergan Aesthetics portfolio. For more information about AbbVie, please visit www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
The "About AbbVie" description above is adapted from AbbVie's standard corporate boilerplate as published in the company's public communications, with pronouns adjusted to third person. Its inclusion is contextual and does not imply any partnership, endorsement, or relationship between AbbVie and Dr. Werschler or TheBestReputation beyond Dr. Werschler's role as a clinical trial investigator.
Mid-year is when income-focused investors tend to take a hard look at their portfolios. With the second half of 2026 ahead, retirees and near-retirees are leaning into reliable dividend payers that can keep checks coming through any summer volatility. The three names below combine long dividend histories, defensive cash flows, and recent raises, exactly the profile that holds up when growth stocks wobble.
Verizon (NYSE: VZ) Verizon (NYSE:VZ | VZ Price Prediction) is the high-yield anchor of this list. The stock trades at $46.95 with a trailing P/E of just 11 and a dividend yield around 6%, well above the broader market. The Q2 2026 payout was raised to $0.7075 per share, up from $0.69 the prior quarter, extending one of the longest uninterrupted dividend streaks in U.S. telecom.
The bull case is straightforward for retirees. Q1 2026 adjusted EPS came in at $1.28, up 8% YoY, and management raised full-year guidance to $4.95 to $4.99 in adjusted EPS with free cash flow of at least $21.5 billion, which more than covers the dividend. The closed Frontier Communications acquisition pushed fiber broadband connections up 42% YoY to roughly 10.8 million, and Verizon posted its first positive Q1 postpaid phone net adds since 2013. CEO Dan Schulman summed it up: “Our turnaround is not only progressing, it is gaining momentum.” Shares are up 16% year to date, yet still trade below the analyst target of $51.85.
Risk to watch: Total debt climbed to $172.5 billion after the Frontier deal, interest expense rose 19% YoY, and postpaid phone churn ticked up to 1%. Leverage will dictate how quickly future raises arrive.
Chevron (NYSE: CVX) Chevron (NYSE:CVX) is the dividend aristocrat of the group. The Q1 2026 dividend was raised to $1.78 per share quarterly, marking the 39th consecutive annual increase. That payment landed in shareholder accounts on June 10, 2026, the same day this article runs. Shares closed at $186.76 on June 9 and have risen 25% year to date, yet the forward P/E sits at a reasonable 14.
The retirement thesis here is fortress cash returns. Chevron posted Q1 2026 adjusted EPS of $1.41 versus $0.97 estimates, its sixth consecutive quarterly EPS beat. Worldwide production rose 15% YoY to 3,858 MBOED, with the Permian Basin now at 1 million BOE/day following Hess integration. Chevron has returned cash on autopilot, posting 16 consecutive quarters returning more than $5 billion to shareholders, including $2.5 billion in Q1 buybacks. CEO Mike Wirth pointed to “the resilience of our portfolio and the value of disciplined execution.”
Risk to watch: Q1 net income fell 37% YoY, free cash flow turned negative at -$1.55 billion on working capital swings, and the net debt ratio crept to 18%. Oil-price sensitivity and Middle East exposure remain the obvious wildcards.
AbbVie (NYSE: ABBV) AbbVie (NYSE:ABBV) rounds out the trio as the healthcare leg. The stock closed at $225.42 on June 9 with a dividend yield near 3% and a forward P/E of 16. The dividend was raised to $1.73 per quarter in 2026, up from $1.64, continuing a march from just $0.40 per quarter in 2013.
The plain-language bull case: the post-Humira transition is going faster than skeptics expected. Q1 2026 revenue hit $15.00 billion, up 12% YoY, beating the $14.72 billion estimate. Skyrizi grew 31% YoY to $4.48 billion, Rinvoq added 23%, and neuroscience expanded 26%. Management raised 2026 adjusted EPS guidance to $14.08 to $14.28. CEO Robert A. Michael said the company is “off to an excellent start in 2026, with first-quarter results exceeding our expectations.” Analysts carry an average target of $253.55.
Risk to watch: Humira sales fell 39% to $688 million as biosimilars bite, Imbruvica dropped 25%, and GAAP earnings remain weighed down by acquired IPR&D charges. Investors will want to see Skyrizi and Rinvoq continue carrying the load past 2028.
What to Watch Next All three names share the traits retirement portfolios tend to prize: long dividend histories, recent raises, defensive end markets, and forward P/E ratios in the low-to-mid teens. Verizon offers the deepest yield, Chevron the longest aristocrat streak, and AbbVie the best growth profile of the group. Keep an eye on Q2 earnings reports later this summer, when each management team will update guidance heading into the second half.
Key Takeaways AbbVie's Skyrizi and Rinvoq drove double-digit Q1 revenue growth with strong sales gains.AbbVie raised its 2026 sales outlook; the drugs are expected to deliver over 20% combined growth.AbbVie is pursuing new indications and label expansions to support continued growth. AbbVie (ABBV - Free Report) continues to see strong momentum from Skyrizi and Rinvoq, its two blockbuster immunology medicines. Sales of both drugs not only mitigated the impact of continued erosion in legacy drug Humira but also reaffirmed their role as AbbVie’s key growth drivers.
This growth continued into 2026. In the first quarter, Skyrizi sales increased 29.2% year over year to $4.48 billion, while Rinvoq sales rose 20.2% to $2.12 billion. Together, the products were key contributors to AbbVie's double-digit revenue growth in the quarter. The company subsequently raised its 2026 revenue outlook for both medicines by $100 million each and now expects Skyrizi and Rinvoq to generate $21.6 billion and $10.2 billion in sales, respectively, this year. Combined, Skyrizi and Rinvoq are expected to deliver more than 20% growth in 2026.
A key driver behind this strength is continued demand across inflammatory bowel disease (IBD) indications, including ulcerative colitis (UC) and Crohn's disease (CD). Skyrizi has emerged as a leading therapy in the category, while Rinvoq continues to gain traction following label expansions that support earlier use in treatment. AbbVie also highlighted continued market-share gains and strong new-patient demand for both products in the first quarter.
The growth runway for both medicines remains substantial. AbbVie recently submitted regulatory applications seeking approval of Rinvoq across two indications — vitiligo and alopecia areata — and Skyrizi as a subcutaneous induction option for CD. Additional growth opportunities remain, with Rinvoq being evaluated in late-stage studies for hidradenitis suppurativa and systemic lupus erythematosus, and data readouts expected later this year. Management believes the next wave of Rinvoq indications alone could contribute roughly $2 billion in peak annual sales. Combined with continued market-share gains across psoriasis and IBD, these label expansion opportunities should support sustained growth for both medicines through 2026 and beyond.
ABBV’s Competition in the Immunology SpaceJohnson & Johnson (JNJ - Free Report) remains one of AbbVie’s strongest competitors in immunology through blockbuster medicines Tremfya and Stelara. While Stelara faces biosimilar competition, J&J continues to strengthen its position with Tremfya, which is approved across multiple immunology indications, including UC and CD. The company also recently gained FDA approval for Icotyde, a new oral immunology therapy that is positioned as a direct competitor to Skyrizi.
Eli Lilly (LLY - Free Report) is also expanding its presence in the immunology space. Its IL-23 inhibitor Omvoh is approved for both UC and CD, broadening Eli Lilly’s footprint in the fast-growing IBD market.
ABBV’s Price Performance, Valuation and EstimatesShares of AbbVie have underperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, AbbVie is trading at a discount to the industry. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 14.81 times forward earnings compared with the industry’s average of 17.67.
Image Source: Zacks Investment Research
Revisions in EPS estimates for 2026 and 2027 have trended higher over the past 30 days.
Image Source: Zacks Investment Research
AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AbbVie (NYSE:ABBV | ABBV Price Prediction) at $224.95 sits at the center of a sharp bull-bear debate. The pharma giant has climbed 53.59% since the start of 2024 off its 2024 lows, but a balance sheet carrying negative shareholders’ equity of -$6.6 billion complicates conviction at this price.
AbbVie is the immunology heavyweight behind Skyrizi, Rinvoq, and legacy Humira, with neuroscience, oncology, and aesthetics portfolios from the 2020 Allergan deal. The stock has run on smoother-than-feared Humira biosimilar transition and aggressive growth from next-generation immunology drugs.
That run has stretched valuation to a trailing P/E near 110 while shareholder equity has flipped negative, leaving the market to decide whether the cash machine deserves a premium or leverage deserves a discount.
Why Skyrizi And Rinvoq Justify The Premium Skyrizi delivered $4.48 billion in Q1 2026 revenue, up 30.9%, and Rinvoq added $2.12 billion, up 23.3%. Both drugs are absorbing Humira’s erosion faster than analysts modeled a year ago.
Management raised FY2026 adjusted EPS guidance to $14.08 to $14.28, the second hike of the cycle. Neuroscience grew 26.0% to $2.88 billion, with Ubrelvy and Qulipta both posting growth above 40%. The Street sees upside, with 24 Buy ratings and an average price target of $253.55.
Free cash flow yield of 4.48% and a 2.93% dividend yield, backed by the $1.73 quarterly payout raised in late 2025, give income investors a paid-to-wait setup with Dividend Aristocrat pedigree.
The Leverage And Patent Cliff Bears Are Watching Total debt sits at $72.86 billion as of Q1 2026, against shareholder equity of -$6.6 billion and retained earnings of -$17.87 billion. Equity has eroded by roughly $13.6 billion in two years.
Interest expense ran $2.89 billion in FY2025 and is structural drag if rates stay elevated. 65.9% of assets are goodwill and intangibles, much tied to Allergan, leaving thin tangible backing for $143 billion in liabilities.
Q1 2026 net income fell 45.7% year over year to $699 million, hit by IPR&D charges and a $2.39 billion contingent consideration adjustment. One in-house AI model pegs fair value at $154.41, implying 31.36% downside.
Why The Middle Ground Wins For Now The Hold case rests on offsetting forces. Skyrizi and Rinvoq are real, the dividend is funded, and the $100 billion U.S. R&D commitment buys three years of tariff and pricing relief. Yet negative book value, a -10.84% ROIC, and patent cliff worry beyond 2028 keep the long-term math fragile.
Adding capital here means paying a high P/E for earnings still eaten by interest, amortization, and acquisition charges. Trimming means giving up a growing dividend and the strongest immunology franchise in pharma. Watching quarterly Skyrizi and Rinvoq sales, debt paydown progress, and pipeline reads from Epkinly, Elahere, or ABBV-295 obesity program is the honest move.
What The Numbers Say ABBV trades at $224.95, with analyst consensus target of $253.55 across 32 covering analysts (24 Buy, 8 Hold, 0 Sell), implying roughly 13% upside if hit. The AI-driven counter-read at $154.41 shows dispersion of views.
The stock is up 22.6% over the past year and roughly flat year to date at +0.07%. The S&P 500 is up 20.29% over the past year and 6.38% year to date, meaning AbbVie matched the index over twelve months but lagged in 2026.
Valuation reads expensive on earnings (P/E near 110) yet reasonable on cash (P/FCF of 22), which is the heart of the debate.
The Verdict On ABBV At $225 At $224.95, AbbVie sits in the middle of the bull-bear debate.
The bull thesis requires continued double-digit growth from Skyrizi and Rinvoq plus successful integration of recent IPR&D bets to refill the pipeline beyond 2028. The bear thesis requires interest expense and amortization to keep suppressing reported earnings while patent cliff fears regain attention. Both paths are live, and current price compensates for neither cleanly.
Existing holders are paid $1.73 a quarter to wait for the next two earnings reports, where Skyrizi and Rinvoq run-rates, GAAP cleanup, and any 2028+ pipeline reads will either confirm the premium or expose it. Investors evaluating fresh capital may find a wider margin of safety closer to $190, where the income stream better offsets negative-equity reality.
The verdict shifts on either sharp deceleration in immunology growth (push toward Sell) or visible deleveraging plus pipeline win that resets 2029 earnings (push toward Buy). Until then, the dividend, leverage trajectory, and valuation relative to recent gains are the metrics that matter most.
At $225, AbbVie looks too leveraged to add aggressively yet too productive to dismiss, which is why the debate stays balanced.
AbbVie Inc. is rated a 'Buy' on accelerating fundamentals, robust pipeline progress, and a macro backdrop favoring defensive growth. SKYRIZI and RINVOQ are projected to deliver ~$31.8 billion in FY2026E revenue, with neuroscience emerging as a second growth pillar targeting ~$12.6 billion. EPS is expected to surge ~43% to $14.26 in FY2026E, with FCF up 54% and net debt/EBITDA declining to 1.6x.
, /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association (EHA) 2026 Congress taking place June 11-14 in Stockholm, Sweden. Final results from the Phase 3 CLL14 trial in previously untreated chronic lymphocytic leukemia (CLL), which was conducted in collaboration with the German CLL Study Group, will be featured in an oral presentation.
"The nine-year results from the landmark Phase 3 CLL14 trial affirm venetoclax's enduring safety and efficacy," said Daejin Abidoye, vice president, therapeutic area head, oncology, solid tumor and hematology, AbbVie. "These data continue to add to the impressive body of evidence supporting the first-line use of venetoclax-based combination regimens in broader CLL patient populations, offering patients unprecedented time to next treatment — and therefore time off treatment — after one year of fixed-duration therapy. This research advances our mission to transform care and deliver better outcomes for patients living with difficult-to-cure blood cancers."
"Venetoclax in combination with obinutuzumab has shown positive responses across several key measures compared to obinutuzumab plus chlorambucil, including an extended increase in progression-free survival in previously untreated patients with chronic lymphocytic leukemia," said Kirsten Fischer, M.D., investigator in the CLL14 study, University Hospital Cologne. "Importantly, with a demonstrated median time to next treatment of approximately eight years, the findings reflect the sustained durability of this combination treatment option with a meaningful time without CLL specific treatment for patients."
A final analysis of the Phase 3 CLL14 trial, conducted in close collaboration with the German CLL Study Group, comparing venetoclax plus obinutuzumab to chlorambucil plus obinutuzumab in previously untreated patients with CLL and coexisting medical conditions, found that venetoclax plus obinutuzumab significantly improved progression-free survival (PFS) compared to chlorambucil plus obinutuzumab, providing a limited-duration treatment option for unfit patients with previously untreated CLL. The nine-year analysis demonstrated the long-term off-treatment efficacy and safety of the venetoclax plus obinutuzumab fixed-duration combination, with the median time to next treatment (TTNT) of 7.6 years.1
After a median follow-up of 9.2 years, treatment with venetoclax plus obinutuzumab resulted in superior PFS compared to the obinutuzumab plus chlorambucil group, with median PFS of 6.4 years versus 3.2 years, respectively (HR 0.50 [95% CI 0.39-0.63], p<0.001). The most frequently occurring Grade 3 (≥2%) adverse events (AEs) in patients receiving the venetoclax-based combination were neutropenia, thrombocytopenia, infusion-related reaction, anemia, febrile neutropenia, pneumonia and leukopenia.1,2
CLL is one of the most common forms of leukemia in adults and is a type of cancer that can develop from cells in the bone marrow that later mature into certain white blood cells (called lymphocytes).3 Patients with CLL often experience relapsed disease, meaning the cancer has returned after previously responding to treatment, while others experience refractory disease when the cancer stops responding to therapy.4 While outcomes have improved in recent years, patients can often face long treatment durations and ongoing disease management challenges.
About the CLL14 Phase 3 Trial2,5,6,7
The prospective, multicenter, open-label, randomized Phase 3 CLL14 trial (NCT02242942), which was conducted in close collaboration with the German CLL Study Group (GCLLSG), evaluated the efficacy and safety of a combined regimen of venetoclax and obinutuzumab (n=216) versus obinutuzumab and chlorambucil (n=216) in previously untreated patients with CLL and co-existing medical conditions (total Cumulative Illness Rating Scale [CIRS] score >6 or creatinine clearance <70 mL/min). The therapies were administered for a fixed duration of 12 months for venetoclax in combination with six cycles of obinutuzumab. The trial enrolled 432 patients, all of whom were previously untreated, according to the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria. Efficacy was based on PFS, as assessed by an independent review committee.
Key secondary endpoints were rates of MRD in peripheral blood and bone marrow and overall and complete response rates.
In patients with CLL receiving venetoclax combination therapy with obinutuzumab, the most frequently occurring Grade 3 (≥2%) adverse events (AEs) were neutropenia, thrombocytopenia, infusion-related reaction, anemia, febrile neutropenia, pneumonia and leukopenia.1,2
About VENCLYXTO
VENCLYXTO® (venetoclax) is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein. In some blood cancers, BCL-2 prevents cancer cells from undergoing their natural death or self-destruction process, called apoptosis. VENCLYXTO targets the BCL-2 protein and works to help restore the process of apoptosis.
VENCLYXTO is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S. Together, the companies are committed to BCL-2 research and to studying venetoclax in clinical trials across several blood and other cancers. Venetoclax is approved in more than 80 countries, including the U.S.
VENCLYXTO (venetoclax) EU Indication and Summary of Important Safety Information
Venclyxto is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL):
in combination with acalabrutinib with or without obinutuzumab in combination with obinutuzumab in combination with ibrutinib VENCLYXTO in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.
VENCLYXTO monotherapy is indicated for the treatment of CLL:
In the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor, or In the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor Contraindications
Hypersensitivity to the active substance or to any of the excipients. Concomitant use of strong CYP3A inhibitors at initiation and during the dose-titration phase. Concomitant use of preparations containing St. John's wort.
Special Warnings & Precautions for Use
Tumour lysis syndrome (TLS), including fatal events and renal failure requiring dialysis, has occurred in patients with CLL when treated with venetoclax. Venetoclax poses a risk for TLS at initiation and during the dose-titration phase. Changes in electrolytes consistent with TLS that require prompt management can occur as early as 6 to 8 hours following the first dose of VENCLYXTO and at each dose increase. During post marketing surveillance, TLS, including fatal events, has been reported after a single 20 mg dose of venetoclax. The risk of TLS is a continuum based on multiple factors, including comorbidities (particularly reduced renal function), tumour burden, and splenomegaly in CLL. Patients should be assessed for risk and should receive appropriate prophylaxis, monitoring, and management for TLS.
Neutropenia (grade 3 or 4) has been reported and complete blood counts should be monitored throughout the treatment period. Serious infections, including sepsis with fatal outcome, have been reported. Monitoring of any signs and symptoms of infection is required. Suspected infections should receive prompt treatment and dose interruption or reduction, as appropriate. Live vaccines should not be administered during treatment or thereafter until B-cell recovery.
Drug Interactions
CYP3A inhibitors: For patients requiring concomitant use with venetoclax, refer to the SmPC for recommendations for managing drug-drug interactions. Patients should be monitored more closely for signs of toxicities and the dose may need to be further adjusted. Grapefruit products, Seville oranges, and starfruit (carambola) should be avoided during treatment with venetoclax.
Additional agents that may alter venetoclax plasma concentrations include P-gp or BCRP inhibitors, CYP3A inducers (including St. John's wort), azithromycin and bile acid sequestrants. Concomitant use of these agents with venetoclax may require further dose adjustments and patients should be monitored closely for signs of toxicities.
Adverse Reactions
The most commonly occurring adverse reactions (≥20%) of any grade in patients receiving venetoclax in the combination studies with obinutuzumab, ibrutinib, or rituximab were diarrhoea, neutropenia, nausea, upper respiratory tract infection, fatigue and vomiting. In the monotherapy studies, the most common adverse reactions were neutropenia/neutrophil count decreased, diarrhoea, nausea, anaemia, fatigue, and upper respiratory tract infection.
The most frequently reported serious adverse reactions (≥2%) in patients receiving venetoclax in combination with obinutuzumab, ibrutinib, or rituximab were pneumonia, febrile neutropenia, sepsis, neutropenia, anaemia, diarrhoea and TLS. In the monotherapy studies, the most frequently reported serious adverse reactions (≥2%) were pneumonia and febrile neutropenia.
The most commonly occurring adverse reactions (≥20%) of any grade in patients treated with venetoclax in combination with acalabrutinib were infections, neutropenia, headache, bruising, diarrhoea and musculoskeletal pain. The most commonly reported Grade ≥3 adverse reaction (≥5%) was neutropenia.
The most commonly occurring adverse reactions of any grade (≥20%) in patients treated with venetoclax in combination with acalabrutinib and obinutuzumab were infections, neutropenia, headache, bruising, diarrhoea, nausea and musculoskeletal pain. The most commonly reported Grade ≥3 adverse reactions (≥5%) were neutropenia and thrombocytopenia.
Discontinuations, dosage reductions and dose interruptions due to adverse reactions have occurred in both venetoclax monotherapy and in combination therapy.
Special Populations
Patients with reduced renal function (CrCl <80 mL/min) may require more intensive prophylaxis and monitoring to reduce the risk of TLS at initiation and during the dose-titration phase. Venetoclax should be administered to patients with severe renal impairment (CrCl ≥15 ml/min and <30 ml/min) or end-stage renal disease (ESRD) requiring dialysis (CrCL <15ml/min) only if the benefit outweighs the risk and patients should be monitored closely for signs of toxicity due to increased risk of TLS.
For patients with severe hepatic impairment, a dose reduction of at least 50% throughout treatment is recommended. These patients should be monitored more closely for signs of toxicity.
Women should avoid becoming pregnant while taking venetoclax and for at least 30 days after ending treatment. Therefore, women of childbearing potential must use highly effective contraceptive measures while taking venetoclax and for 30 days after stopping treatment. Venetoclax may harm the foetus when administered to a pregnant woman. Breast-feeding should be discontinued during treatment with venetoclax.
This is not a complete summary of all safety information. Refer to the prescribing information of each of the medicinal products used in combination with venetoclax for additional information for management of toxicities. See VENCLYXTO (venetoclax) SmPC at www.ema.europa.eu. Globally, prescribing information varies. Refer to the individual country product label for complete information.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
About AbbVie in Oncology
AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.
Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Contacts:
_________________________________
1
Fischer K, Al-Sawaf O ,et al. Venetoclax-obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia: Final Results of the Randomized CLL14 Study. Abstract EHA-2488 presented at the European Hematology Association Congress 2026. Stockholm, Sweden.
2
Fischer K, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380:2225-2236.
3
American Cancer Society. Leukemia – Chronic Lymphocytic Leukemia. Available at: https://www.cancer.org/cancer/types/chronic-lymphocytic-leukemia/about/what-is-cll.html. Accessed June 2026.
4
Nastoupil L, Flowers C. Management of relapsed chronic lymphocytic leukemia: applying guidelines to practice. Community Oncol. 2012; 9(12): S85–S92. doi:10.1016/j.cmonc.2012.09.019.
5
Clinicaltrials.gov. NCT02242942: A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare The Efficacy and Safety of A Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and Chlorambucil in Previously Untreated Patients With CLL and Coexisting Medical Conditions. Accessed June 2026.
6
Summary of Product Characteristics for VENCLYXTO (venetoclax). Ludwigshafen, Germany: AbbVie Deutschland GmbH & Co. KG.
7
VENCLEXTA (venetoclax) [Package Insert]. North Chicago, Ill.: AbbVie Inc
, /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association (EHA) 2026 Congress taking place June 11-14 in Stockholm, Sweden. Final results from the Phase 3 CLL14 trial in previously untreated chronic lymphocytic leukemia (CLL), which was conducted in collaboration with the German CLL Study Group, will be featured in an oral presentation.
"The nine-year results from the landmark Phase 3 CLL14 trial affirm venetoclax's enduring safety and efficacy," said Daejin Abidoye, vice president, therapeutic area head, oncology, solid tumor and hematology, AbbVie. "These data continue to add to the impressive body of evidence supporting the first-line use of venetoclax-based combination regimens in broader CLL patient populations, offering patients unprecedented time to next treatment — and therefore time off treatment — after one year of fixed-duration therapy. This research advances our mission to transform care and deliver better outcomes for patients living with difficult-to-cure blood cancers."
"Venetoclax in combination with obinutuzumab has shown positive responses across several key measures compared to obinutuzumab plus chlorambucil, including an extended increase in progression-free survival in previously untreated patients with chronic lymphocytic leukemia," said Kirsten Fischer, M.D., investigator in the CLL14 study, University Hospital Cologne. "Importantly, with a demonstrated median time to next treatment of approximately eight years, the findings reflect the sustained durability of this combination treatment option with a meaningful time without CLL specific treatment for patients."
A final analysis of the Phase 3 CLL14 trial, conducted in close collaboration with the German CLL Study Group, comparing venetoclax plus obinutuzumab to chlorambucil plus obinutuzumab in previously untreated patients with CLL and coexisting medical conditions, found that venetoclax plus obinutuzumab significantly improved progression-free survival (PFS) compared to chlorambucil plus obinutuzumab, providing a limited-duration treatment option for unfit patients with previously untreated CLL. The nine-year analysis demonstrated the long-term off-treatment efficacy and safety of the venetoclax plus obinutuzumab fixed-duration combination, with the median time to next treatment (TTNT) of 7.6 years.1
After a median follow-up of 9.2 years, treatment with venetoclax plus obinutuzumab resulted in superior PFS compared to the obinutuzumab plus chlorambucil group, with median PFS of 6.4 years versus 3.2 years, respectively (HR 0.50 [95% CI 0.39-0.63], p<0.001). The most frequently occurring Grade 3 (≥2%) adverse events (AEs) in patients receiving the venetoclax-based combination were neutropenia, thrombocytopenia, infusion-related reaction, anemia, febrile neutropenia, pneumonia and leukopenia.1,2
CLL is one of the most common forms of leukemia in adults and is a type of cancer that can develop from cells in the bone marrow that later mature into certain white blood cells (called lymphocytes).3 Patients with CLL often experience relapsed disease, meaning the cancer has returned after previously responding to treatment, while others experience refractory disease when the cancer stops responding to therapy.4 While outcomes have improved in recent years, patients can often face long treatment durations and ongoing disease management challenges.
About the CLL14 Phase 3 Trial2,5,6,7
The prospective, multicenter, open-label, randomized Phase 3 CLL14 trial (NCT02242942), which was conducted in close collaboration with the German CLL Study Group (GCLLSG), evaluated the efficacy and safety of a combined regimen of venetoclax and obinutuzumab (n=216) versus obinutuzumab and chlorambucil (n=216) in previously untreated patients with CLL and co-existing medical conditions (total Cumulative Illness Rating Scale [CIRS] score >6 or creatinine clearance <70 mL/min). The therapies were administered for a fixed duration of 12 months for venetoclax in combination with six cycles of obinutuzumab. The trial enrolled 432 patients, all of whom were previously untreated, according to the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria. Efficacy was based on PFS, as assessed by an independent review committee.
Key secondary endpoints were rates of MRD in peripheral blood and bone marrow and overall and complete response rates.
In patients with CLL receiving venetoclax combination therapy with obinutuzumab, the most frequently occurring Grade 3 (≥2%) adverse events (AEs) were neutropenia, thrombocytopenia, infusion-related reaction, anemia, febrile neutropenia, pneumonia and leukopenia.1,2
About VENCLYXTO
VENCLYXTO® (venetoclax) is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein. In some blood cancers, BCL-2 prevents cancer cells from undergoing their natural death or self-destruction process, called apoptosis. VENCLYXTO targets the BCL-2 protein and works to help restore the process of apoptosis.
VENCLYXTO is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S. Together, the companies are committed to BCL-2 research and to studying venetoclax in clinical trials across several blood and other cancers. Venetoclax is approved in more than 80 countries, including the U.S.
VENCLYXTO (venetoclax) EU Indication and Summary of Important Safety Information
Venclyxto is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL):
in combination with acalabrutinib with or without obinutuzumab in combination with obinutuzumab in combination with ibrutinib VENCLYXTO in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.
VENCLYXTO monotherapy is indicated for the treatment of CLL:
In the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor, or In the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor Contraindications
Hypersensitivity to the active substance or to any of the excipients. Concomitant use of strong CYP3A inhibitors at initiation and during the dose-titration phase. Concomitant use of preparations containing St. John's wort.
Special Warnings & Precautions for Use
Tumour lysis syndrome (TLS), including fatal events and renal failure requiring dialysis, has occurred in patients with CLL when treated with venetoclax. Venetoclax poses a risk for TLS at initiation and during the dose-titration phase. Changes in electrolytes consistent with TLS that require prompt management can occur as early as 6 to 8 hours following the first dose of VENCLYXTO and at each dose increase. During post marketing surveillance, TLS, including fatal events, has been reported after a single 20 mg dose of venetoclax. The risk of TLS is a continuum based on multiple factors, including comorbidities (particularly reduced renal function), tumour burden, and splenomegaly in CLL. Patients should be assessed for risk and should receive appropriate prophylaxis, monitoring, and management for TLS.
Neutropenia (grade 3 or 4) has been reported and complete blood counts should be monitored throughout the treatment period. Serious infections, including sepsis with fatal outcome, have been reported. Monitoring of any signs and symptoms of infection is required. Suspected infections should receive prompt treatment and dose interruption or reduction, as appropriate. Live vaccines should not be administered during treatment or thereafter until B-cell recovery.
Drug Interactions
CYP3A inhibitors: For patients requiring concomitant use with venetoclax, refer to the SmPC for recommendations for managing drug-drug interactions. Patients should be monitored more closely for signs of toxicities and the dose may need to be further adjusted. Grapefruit products, Seville oranges, and starfruit (carambola) should be avoided during treatment with venetoclax.
Additional agents that may alter venetoclax plasma concentrations include P-gp or BCRP inhibitors, CYP3A inducers (including St. John's wort), azithromycin and bile acid sequestrants. Concomitant use of these agents with venetoclax may require further dose adjustments and patients should be monitored closely for signs of toxicities.
Adverse Reactions
The most commonly occurring adverse reactions (≥20%) of any grade in patients receiving venetoclax in the combination studies with obinutuzumab, ibrutinib, or rituximab were diarrhoea, neutropenia, nausea, upper respiratory tract infection, fatigue and vomiting. In the monotherapy studies, the most common adverse reactions were neutropenia/neutrophil count decreased, diarrhoea, nausea, anaemia, fatigue, and upper respiratory tract infection.
The most frequently reported serious adverse reactions (≥2%) in patients receiving venetoclax in combination with obinutuzumab, ibrutinib, or rituximab were pneumonia, febrile neutropenia, sepsis, neutropenia, anaemia, diarrhoea and TLS. In the monotherapy studies, the most frequently reported serious adverse reactions (≥2%) were pneumonia and febrile neutropenia.
The most commonly occurring adverse reactions (≥20%) of any grade in patients treated with venetoclax in combination with acalabrutinib were infections, neutropenia, headache, bruising, diarrhoea and musculoskeletal pain. The most commonly reported Grade ≥3 adverse reaction (≥5%) was neutropenia.
The most commonly occurring adverse reactions of any grade (≥20%) in patients treated with venetoclax in combination with acalabrutinib and obinutuzumab were infections, neutropenia, headache, bruising, diarrhoea, nausea and musculoskeletal pain. The most commonly reported Grade ≥3 adverse reactions (≥5%) were neutropenia and thrombocytopenia.
Discontinuations, dosage reductions and dose interruptions due to adverse reactions have occurred in both venetoclax monotherapy and in combination therapy.
Special Populations
Patients with reduced renal function (CrCl <80 mL/min) may require more intensive prophylaxis and monitoring to reduce the risk of TLS at initiation and during the dose-titration phase. Venetoclax should be administered to patients with severe renal impairment (CrCl ≥15 ml/min and <30 ml/min) or end-stage renal disease (ESRD) requiring dialysis (CrCL <15ml/min) only if the benefit outweighs the risk and patients should be monitored closely for signs of toxicity due to increased risk of TLS.
For patients with severe hepatic impairment, a dose reduction of at least 50% throughout treatment is recommended. These patients should be monitored more closely for signs of toxicity.
Women should avoid becoming pregnant while taking venetoclax and for at least 30 days after ending treatment. Therefore, women of childbearing potential must use highly effective contraceptive measures while taking venetoclax and for 30 days after stopping treatment. Venetoclax may harm the foetus when administered to a pregnant woman. Breast-feeding should be discontinued during treatment with venetoclax.
This is not a complete summary of all safety information. Refer to the prescribing information of each of the medicinal products used in combination with venetoclax for additional information for management of toxicities. See VENCLYXTO (venetoclax) SmPC at www.ema.europa.eu. Globally, prescribing information varies. Refer to the individual country product label for complete information.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
About AbbVie in Oncology
AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.
Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Contacts:
_________________________________
1
Fischer K, Al-Sawaf O ,et al. Venetoclax-obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia: Final Results of the Randomized CLL14 Study. Abstract EHA-2488 presented at the European Hematology Association Congress 2026. Stockholm, Sweden.
2
Fischer K, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380:2225-2236.
3
American Cancer Society. Leukemia – Chronic Lymphocytic Leukemia. Available at: https://www.cancer.org/cancer/types/chronic-lymphocytic-leukemia/about/what-is-cll.html. Accessed June 2026.
4
Nastoupil L, Flowers C. Management of relapsed chronic lymphocytic leukemia: applying guidelines to practice. Community Oncol. 2012; 9(12): S85–S92. doi:10.1016/j.cmonc.2012.09.019.
5
Clinicaltrials.gov. NCT02242942: A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare The Efficacy and Safety of A Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and Chlorambucil in Previously Untreated Patients With CLL and Coexisting Medical Conditions. Accessed June 2026.
6
Summary of Product Characteristics for VENCLYXTO (venetoclax). Ludwigshafen, Germany: AbbVie Deutschland GmbH & Co. KG.
7
VENCLEXTA (venetoclax) [Package Insert]. North Chicago, Ill.: AbbVie Inc
DENVER--(BUSINESS WIRE)--SSR Mining Inc. (Nasdaq/TSX: SSRM) (“SSR Mining” or the “Company”) announces that each of the eight nominees listed in the Proxy Statement for the 2026 Annual Meeting of Shareholders (the “Meeting”) were elected as directors of SSR Mining on Thursday, May 7, 2026. Voting results for the election of directors are set out below:
Nominee Name
Votes For
% For
Votes Withheld
% Withheld
Broker Non Vote
Rod Antal
145,639,711
98.69%
1,938,333
1.31%
15,402,274
Thomas R. Bates, Jr.
90,845,964
61.56%
56,732,081
38.44%
15,402,273
Brian R. Booth
146,243,280
99.10%
1,334,764
0.90%
15,402,274
Alan P. Krusi
145,353,727
98.49%
2,224,317
1.51%
15,402,274
Daniel Malchuk
144,910,353
98.19%
2,667,691
1.81%
15,402,274
Laura Mullen
145,801,559
98.80%
1,776,486
1.20%
15,402,273
Kay Priestly
140,344,130
95.10%
7,233,914
4.90%
15,402,274
Karen Swager
123,223,257
83.50%
24,354,788
16.50%
15,402,273
At the Meeting, the shareholders of SSR Mining also approved (i) a non-binding advisory resolution regarding the Company’s approach to executive compensation, and (ii) the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
The voting results for each resolution are set out below:
Votes For
% For
Votes Against
% Against
Votes Withheld
% Withheld
Broker Non Vote
Advisory Vote on
Executive Compensation
79,296,143
53.73%
66,819,982
45.28%
1,461,909
0.99%
15,402,284
Appointment of Auditors
162,777,275
99.88%
0
0.00%
203,043
0.12%
0
About SSR Mining
SSR Mining is listed under the ticker symbol SSRM on the Nasdaq and the TSX.
For more information, please visit: www.ssrmining.com.
Insider Selling: MarketAxess (NASDAQ:MKTX) General Counsel Sells 100 Shares of StockMarketBeat
MarketAxess Holdings Inc. (NASDAQ:MKTX - Get Free Report) General Counsel Scott Pintoff sold 100 shares of the stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $116.03, for a total transaction of $11,603.00. Following the transaction, the general counsel owned 11,786 shares in the company, valued at approximately $1,367,529.58. The trade was a 0.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
NASDAQ:MKTX
Read Insider Selling: MarketAxess (NASDAQ:MKTX) General Counsel Sells 100 Shares of Stock
Trending News All MarketBeat Instant News Alerts Sort By
Time Frame
Alert Type
Keywords
Page 1 of 327
Get 30 Days of MarketBeat All Access for Free
Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools.
Start Your 30-Day Trial
Sign in to your free account to enjoy these benefits
In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer.
SSR Mining (SSRM) is rated Buy, reflecting its Americas-focused pivot and strong performance, though no longer a Strong Buy after a significant rally since upgrading them. Q1 results exceeded EPS and revenue estimates, with $210.78M in free cash flow despite production being weighted toward H2 and AISC pressures. The Çöpler sale ($1.5B) is expected to close by the end of Q3 2026, unlocking capital for growth, buybacks, and reducing Turkey-related risk, supporting a potential re-rating as they pivot.
SSR Mining (SSRM - Free Report) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.
The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.
Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.
Therefore, the Zacks rating upgrade for SSR Mining basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.
Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.
For SSR Mining, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.
Harnessing the Power of Earnings Estimate RevisionsEmpirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .
Earnings Estimate Revisions for SSR MiningThis precious metals mining company is expected to earn $4.29 per share for the fiscal year ending December 2026, which represents no year-over-year change.
Analysts have been steadily raising their estimates for SSR Mining. Over the past three months, the Zacks Consensus Estimate for the company has increased 8.1%.
Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
You can learn more about the Zacks Rank here >>>
The upgrade of SSR Mining to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
DENVER--(BUSINESS WIRE)--SSR Mining Inc. (Nasdaq/TSX: SSRM) ("SSR Mining" or the “Company") announces that it has entered into a definitive agreement with Lidya Mines to sell its 20% ownership stake and its operatorship position in the Hod Maden development project (the “Project”) for an uncapped 4.0% net smelter return royalty (“NSR”) on 100% of the Project (the “Transaction”).
The royalty consideration received by SSR Mining is expected to deliver an accretive outcome for shareholders. Concurrently with the Transaction, Royal Gold, Inc. (“Royal Gold”), which is a partner in the Project, will sell 15% of its ownership interest in the Project to Lidya Mines in exchange for an uncapped 2.5% NSR on 100% of the Project. Royal Gold’s 2.5% NSR will be issued with substantially the same key terms as the 4.0% NSR issued to SSR Mining. Royal Gold will also hold a fixed price call right to acquire 2.0% of the NSR from SSR Mining for $160 million, expiring 12 months following declaration of commercial production at the Project. Additionally, Royal Gold will hold a consent right on the sale of SSR Mining's NSR prior to January 1, 2028, and a right of first refusal in connection with any sale of the SSR Mining NSR.
Upon entering into the agreements related to the Transaction, Lidya Mines will become operator of the Project. Upon closing of the Transaction, Lidya Mines will own 85% and Royal Gold will own 15% of the Project.
SSR Mining’s total invested capital into Hod Maden, inclusive of upfront acquisition cost, earn-in and capital spend to date is approximately $243 million. With the announcement of this Transaction, SSR Mining will resign as project operator and will have no further funding obligations, with such obligations being assumed by Lidya Mines. The Transaction will be completed on an as-is, where-is basis and SSR Mining will not provide any material post-closing indemnities. The Transaction is expected to close in the third quarter of 2026. The closing of the Transaction will be subject to receipt of regulatory approval from the Turkish General Directorate of Mining and Petroleum Affairs, as well as other consents and approvals that may be required in connection with the Transaction, and other customary conditions.
The Transaction, together with the previously announced sale of the Çöpler mine in Türkiye and acquisition of the Cripple Creek & Victor Mine in Colorado, completes SSR Mining’s strategic refocus to an Americas platform. These transactions reinforce the Company’s position as a leading free cash flow, capital returns-focused gold and silver producer, anchored by its long-lived Marigold and Cripple Creek & Victor operations in the United States.
Following the closing of the Transaction, the 4.0% Hod Maden NSR will strengthen SSR Mining’s existing royalty portfolio, which currently includes NSRs on the San Luis project (4.0%) owned by Highlander Silver, the Pitarrilla project (1.25%) owned by Endeavour Silver, the Rowan property (3.0%) owned by West Red Lake Gold, and the Sunrise Lake property (4.0%) owned by Honey Badger Silver.
About SSR Mining
SSR Mining is listed under the ticker symbol SSRM on the Nasdaq Stock Market and the Toronto Stock Exchange.
For more information, please visit: www.ssrmining.com.
Cautionary Note Regarding Forward-Looking Information and Statements:
This press release includes “forward looking information” within the meaning of applicable securities laws. Forward-looking information can be identified by terminology such as “may”, “will”, “could”, “should”, “expect”, “plan”, “anticipate”, “believe”, “intend”, “estimate”, “projects”, “predict”, “potential”, “continue” or other similar expressions concerning matters that are not historical facts. Statements that refer to projections of our future financial performance, our anticipated growth and trends in our businesses, and other characterizations of future events or circumstances are forward-looking statements, and include, but are not limited to, our ability successfully close the Transaction or our previously announced agreement to sell the Çöpler mine to Cengiz Holding A.Ş. (the “Çöpler Transaction”) within the time periods anticipated, or at all; our ability to obtain any necessary regulatory or other approvals or consents for the Transaction or the Çöpler Transaction that may be required; the successful completion of the Project and the ability of Lidya Mines to generate revenues from the Project; our ability to receive revenues under, and realize the expected returns from, the NSR, and whether and when we elect, and are able, to monetize the NSR; and our ability to strategically refocus our business to the Americas.
Although we believe that the expectations and assumptions on which such forward-looking information and statements are based are reasonable, you should not place undue reliance on the forward-looking information and statements because we can give no assurance that they will prove to be correct. Forward-looking information and statements are subject to various risks and uncertainties which could cause actual results and expectations to differ materially from the anticipated results or expectations expressed in this press release. Important factors that could cause actual results to differ materially from our historical experience, and present projections and expectations are disclosed in our filings that we make on SEDAR+ at www.sedarplus.ca, and on EDGAR at www.sec.gov, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions. Forward-looking information and statements speak only as of the date they are made. Other than as required by law, we do not intend, and undertake no obligation to update any forward-looking information and statements to reflect, among other things, new information or events. The information contained on, or that may be accessed through, our website is not incorporated by reference into, and is not a part of, this document.
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
#1 (Strong Buy) stocks have produced an unmatched +23.7% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: SSR Mining (SSRM - Free Report) SSR Mining Inc. is a precious metals miner engaged in the operation, acquisition, exploration and development of gold and silver assets across four key jurisdictions: the United States, Türkiye, Canada and Argentina. Incorporated in British Columbia in 2005, the company is headquartered in Denver, Colorado.
SSRM is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.
Additionally, the company could be a top pick for growth investors. SSRM has a Growth Style Score of A, forecasting year-over-year earnings growth of 113.4% for the current fiscal year.
Two analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.52 to $4.29 per share. SSRM also boasts an average earnings surprise of +54%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, SSRM should be on investors' short list.
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: SSR Mining (SSRM - Free Report) SSR Mining Inc. is a precious metals miner engaged in the operation, acquisition, exploration and development of gold and silver assets across four key jurisdictions: the United States, Türkiye, Canada and Argentina. Incorporated in British Columbia in 2005, the company is headquartered in Denver, Colorado.
SSRM is a #1 (Strong Buy) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 6.76; value investors should take notice.
Two analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.61 to $4.38 per share. SSRM also boasts an average earnings surprise of +54%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, SSRM should be on investors' short list.
SSR Mining Inc. is transitioning to a cleaner, Americas-focused gold and silver producer after divesting its Çöpler asset, reducing geopolitical and operational risk. Q1 2026 results demonstrated strong cash flow generation, with $299.6M operating and $210.8M free cash flow, supporting a portfolio re-rating thesis for SSRM. SSRM's key assets, like CC&V and Puna, are delivering high margins and cash flow, while Marigold and Seabee require monitoring for cost and production execution.
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: SSR Mining (SSRM - Free Report) SSR Mining Inc. is a precious metals miner engaged in the operation, acquisition, exploration and development of gold and silver assets across four key jurisdictions: the United States, Türkiye, Canada and Argentina. Incorporated in British Columbia in 2005, the company is headquartered in Denver, Colorado.
SSRM is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
Momentum investors should take note of this Basic Materials stock. SSRM has a Momentum Style Score of A, and shares are up 1.3% over the past four weeks.
Two analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.61 to $4.38 per share. SSRM boasts an average earnings surprise of +54%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, SSRM should be on investors' short list.
Precious metals were on an absolute tear coming into 2026. In January, gold prices reached $5,500 an ounce, while silver hit $121 per ounce. Precious metals prices are soaring amid rising geopolitical uncertainty and growing fiscal deficits, creating a favorable backdrop for gold and silver miners like Denver-based SSR Mining (SSRM +3.46%).
In the past year, the mid-cap mining stock has surged 160% as gold miners ride the wave of rising precious metal prices. The company recently sold its Copler Mine for $1.5 billion, shoring up its balance sheet and giving it a record cash stockpile. Here's why this could be a positive sign for the gold miner moving forward.
Image source: Getty Images.
SSR Mining is fortifying its balance sheet Earlier this year, SSR Mining agreed to sell its 80% stake in the Copler mine in Turkey. The move accomplished a couple of things for the company. For one, it helps reduce SSR's exposure to emerging markets and gets it out of the troubled mine that regulators shut down in 2024 following a fatal accident. The sale allows SSR Mining to focus on lower-risk, Americas-focused gold and silver.
In addition, the sale provides SSR Mining with a huge cash windfall. The company is already coming off a stellar year during which it generated free cash flow of $242 million. In the first quarter, free cash flow was an impressive $211 million, and the company ended the quarter with $634 million in cash, total liquidity of $1.1 billion, and no debt.
When the Copler sale goes through, it will add another $1.5 billion to its stockpile, giving it ammunition for potential acquisitions and cash for dividends or stock buybacks.
Today's Change
(
3.46
%) $
0.91
Current Price
$
27.23
The gold miner is hedged for rising diesel prices SSR Mining remains on track to meet its 2026 full-year production guidance of 450,000 to 535,000 gold equivalent ounces, with production heavily weighted toward the second half of the year. One concern for its investors is rising fuel prices, as oil prices remain elevated amid the ongoing conflict in Iran.
Fuel accounts for roughly 10% of SSR's total operating costs, and a $10-per-barrel increase from here would translate into a $7 to $10 increase in all-in sustaining costs (ASIC) for the rest of the year. The company uses hedges and has hedged 70% of its diesel fuel usage with zero-cost collars that extend through the end of this year.
Analyst covering the company project non-GAAP earnings per share of $4.59 this year, and after its recent 15% pullback from its 52-week high, the stock is now priced at 6.7 times this year's projected earnings. With its strengthening balance sheet and the potential for higher gold prices, SSR Mining is a cheap mining stock to scoop up today for those bullish on the future of precious metals.
Vancouver, British Columbia--(Newsfile Corp. - June 1, 2026) - Phenom Resources Corp. (TSXV: PHNM) (FSE: 1PY0) ("Phenom" or the "Company") is pleased to announce a letter of intent governing an expected non-brokered private placement investment in Phenom by SSR Mining Inc. ("SSR") and proposed joint venture with SSR for the Company's Dobbin Property located in Nevada.
SSR Mining Inc. is a US$6.5B Denver-based gold and silver mining company and the third largest gold producer in the United States. SSR Mining has a portfolio of operating, development and exploration assets across the Americas, including locations in the USA, Canada, and Argentina.
SSR's core operating assets include:
Marigold mine: An open-pit gold mine in Nevada, USA. Cripple Creek & Victor (CC&V) mine: An open-pit gold mine in Colorado, USA. Seabee mine: An underground gold mine in Saskatchewan, Canada. Puna operations: Located in the Jujuy province, Puna is the largest silver mine in ArgentinaPrivate Placement - Strategic Investment
It is proposed that SSR will become a strategic investor in the Company through the non-brokered private placement purchase of 9.9% of the Company's issued and outstanding common shares (calculated on a non-diluted basis, after giving effect to this share issuance) (the "Strategic Investment"). Consequently, under the Strategic Investment, the Company proposes to issue 13,518,353 common shares (the "Shares") to SSR at a price of CAD$0.40/share for total proceeds of CAD$5,407,341.20 (approx. US$3,917,370). The proceeds received from the Strategic Investment are proposed to be used as follows: (i) US$1.3 million will be used towards the remaining payment and work commitments owed by the Company to fully earn a 100% interest in the Dobbin Project; (ii) US$2.5 million will be available for unallocated general working capital of the Company; and (iii) the balance (approx. US$117,370) will be used for general working capital purposes relating to the Dobbin Project.
The Shares will be subject to a statutory hold period expiring four months and one day after their issuance, in accordance with applicable securities laws and the policies of the TSX Venture Exchange (the "TSXV"). In addition, SSR has agreed to voluntarily restrict the disposition of the Shares for a period of one (1) year from the closing date (the "Restricted Period"); provided that SSR may sell up to an aggregate of 500,000 Shares in any calendar month during the Restricted Period, upon prior written notice to Phenom. This limit is fixed for each month, and any undisposed Shares for a particular month will not be added to the next or any succeeding month's limit.
In conjunction with the Strategic Investment, it is proposed that the Company will grant to SSR, for so long as SSR holds a 4.9% or greater ownership interest in Phenom, the right, at the sole discretion of SSR, to maintain that level of ownership interest or to increase its ownership percentage up to a maximum of 19.9% of the outstanding Phenom shares, through participation and top-up rights.
The Strategic Investment is subject to the approval of the TSXV.
Sale of 15% Interest in Dobbin Project and Resulting JV
As part of the non-binding letter of intent ("LOI"), Phenom and SSR have also agreed upon a framework for the sale by Phenom of a 15% interest in the Dobbin Project to SSR for a further US$4,000,000.00, and the consequent joint venture arrangement to be carried on by the two companies in respect of the Dobbin Project. It is proposed that all funds paid by SSR to purchase its 15% interest will be used to advance the Dobbin Project. The LOI provides a binding two-year standstill provision and imposes standard confidentiality obligations on the parties.
The LOI also provides for a binding 30-day exclusivity period, during which time the parties have agreed to negotiate exclusively towards the execution of a definitive agreement relating to the Dobbin Project transaction. There can be no assurance that the parties will enter into a definitive agreement or that the proposed transactions will be completed. The Company will provide updates on the transactions if and when they become available.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States of America. The securities have not been and will not be registered under the United States Securities Act of 1933 (the "1933 Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as defined in the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration is available.
About Phenom Resources Corp.
Phenom has 100% interest in the Carlin Gold-Vanadium Project, located six miles south from the town of Carlin, Nevada, and Highway I-80 in Elko County, which hosts the Carlin Vanadium deposit, North America's largest highest grade primary vanadium resource. The Company has 100% interest in Crescent Valley gold Project, a Bonanza high grade gold vein-type target and an IOCG target and options on two gold projects in Nevada - the Dobbin and King Solomon Properties, which are Carlin Gold-type targets.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking information
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events or the Company's future performance and include, but is not limited to, statements regarding the intended use of proceeds of the Offering, including funding work programs on the Company's exploration properties and for general working capital purposes, the receipt of final approval of the TSX Venture Exchange, and other statements that are not historical facts. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether or not such results will be achieved. Actual results could differ materially from those anticipated due to a number of factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. Readers should not place undue reliance on forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities regulations.
Not for distribution to United States newswire services or for dissemination in the United States.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/299597
Source: Phenom Resources Corp.
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: SSR Mining (SSRM - Free Report) SSR Mining Inc. is a precious metals miner engaged in the operation, acquisition, exploration and development of gold and silver assets across four key jurisdictions: the United States, Türkiye, Canada and Argentina. Incorporated in British Columbia in 2005, the company is headquartered in Denver, Colorado.
SSRM is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
Additionally, the company could be a top pick for growth investors. SSRM has a Growth Style Score of A, forecasting year-over-year earnings growth of 117.9% for the current fiscal year.
Two analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.61 to $4.38 per share. SSRM also boasts an average earnings surprise of +54%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, SSRM should be on investors' short list.
Gold and silver are eternally attractive metals, but lately they haven't been ideal investments. On recent declines in the prices of the two, SSR Mining (SSRM +3.46%) -- which mines both metals -- saw its stock price decrease by more than 3% on Tuesday.
The yield problem The rout in precious metals started last Friday, just after the federal government's Bureau of Labor Statistics released its latest monthly employment report. The striking feature of this digest was the 172,000 new jobs created in May, far higher than the consensus estimate of 80,000. Immediately, and understandably, this led to widespread speculation that the Federal Reserve is more likely to raise than cut interest rates in the near future.
Image source: Getty Images.
This triggered a sell-off in bonds, since higher rates mean higher interest paid on future issues. When a bond's price falls, its yield rises. That makes these yield-bearing investments especially attractive when compared to nonyielding investments -- gold and silver don't pay coupons, after all. Subject to that dynamic, precious metals have generally been on the downswing since Friday.
Broadly speaking, companies that mine precious and base metals are pure plays. What's more, mining is a capital-intensive activity with many fixed costs. Therefore, movements in gold/silver/etc. prices can and will disproportionately affect the performance of the SSR Minings of this world.
Today's Change
(
3.46
%) $
0.91
Current Price
$
27.23
Diminished shine Many might consider these latest price movements corrections, as both gold and silver had sustained bull runs that culminated in all-time highs at the beginning of this year. SSR Mining was indisputably a beneficiary of this, to the point where it has sufficient financial "padding" to withstand a downturn. Still, I think the possibility of rate hikes will rise, if anything, so now might be a good time for current stockholders to sell out of their positions.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
On June 09, 2026, SSR Mining Inc SSRM shares fell 3.3% today to a current price of $25.72. This decline is notable within the context of a 52-week range that has seen a high of $36.52 and a low of $11.70.
GF Value™ verdict indicates that the stock is priced at $25.72, which is 23.7% above the estimated fair value of $20.79.GF Score™ of 72/100 suggests that SSRM is performing above average relative to its peers.Financial strength is strong, with a rating of 9/10, indicating robust financial health. Is SSRM Overvalued or Undervalued? Based on the current price of $25.72 and the GF Value™ of $20.79, SSR Mining Inc appears to be overvalued by approximately 23.7%. This means that there may be limited margin of safety for new investors at this price point. The GF Valuation label of "Modestly Overvalued" further supports this assessment, indicating that the stock may not be an attractive purchase at current levels. If the market adjusts to align the price closer to the GF Value™, investors could face a potential decline.
GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. Given the current overvaluation, there may be risks associated with buying the stock, as it could be susceptible to price corrections in the near term.
How Does SSRM's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 24.3x 15.3x Forward P/E 5.8x N/A SSR Mining's current P/E ratio of 24.3x is significantly above its 5-year median of 15.3x, indicating that the stock is trading at a premium compared to its historical valuation. This analysis aligns with the GF Value™ verdict of being overvalued, suggesting that the current price is not supported by historical earnings metrics.
What Does SSRM's GF Score™ Tell Us? Metric Rating GF Score™ 72/100 Financial Strength 9/10 Profitability 7/10 Growth 7/10 Valuation 5/10 Momentum 1/10 The GF Score™ of 72/100 signifies that SSR Mining Inc is performing above average compared to its peers. The strongest area is its financial strength, with a score of 9/10, indicating excellent financial health. Conversely, the momentum rank of 1/10 highlights weakness in its recent price performance, which may raise concerns about future stock price stability and growth.
What Are Insiders Doing with SSRM Stock? In the last three months, there have been no insider transactions reported for SSR Mining Inc. This lack of activity suggests that insiders may not currently view the stock as an attractive buying opportunity, or they may be awaiting further developments before making any trades.
What This Means for Investors Based on the information presented, SSR Mining Inc appears to be overvalued at its current price of $25.72 as compared to the GF Value™ of $20.79. Investors may want to consider this valuation before making any decisions regarding SSRM stock.
For the complete analysis, visit the SSR Mining Inc SSRM stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is SSRM's GF Score™?
SSRM's GF Score™ is 72/100, indicating that it is performing above average relative to its peers.
Is SSRM overvalued or undervalued?
According to GF Value™, SSRM is overvalued, with its current price being 23.7% above the estimated fair value.
What is SSRM's P/E ratio?
SSRM's P/E ratio is 24.3x, which is significantly above its 5-year median of 15.3x, indicating it is trading at a premium compared to its historical valuation.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
GME stock is moving. See the chart and price action here. Cohen joined Anthony Pompliano on the "From the Desk of Anthony Pompliano" podcast and explained why he wants to acquire eBay.
“I Want to Own eBay“GameStop has proposed acquiring eBay for $125 per share in a half-cash, half-stock deal, with Cohen saying GameStop has about $9 billion in cash and a $20 billion financing commitment from bankers.
He framed the bid as a shareholder-friendly combination that would let eBay investors take part cash while rolling the rest into a combined company led by him.
"It’s within my circle of competence," Cohen said. "It’s a business that I understand. It’s the second-largest e-commerce asset in the United States."
Cohen argued eBay is "under earning" and said he could "make a really big impact in terms of the profitability in the short term, but more important in the long term."
"It’s something where I want to run eBay. I want to own eBay. I want eBay to be a much, much larger business," Cohen said.
He said his Chewy experience is central to the thesis.
"E-commerce is in my wheelhouse and there’s no asset in my view that has as much potential as eBay," Cohen said.
Cohen is UndeterredeBay rejected GameStop's proposal, calling the offer "not credible or attractive."
Cohen argued the response was expected, saying the deal is "not attractive to the board and the management team" because they would be replaced, but "it's very attractive to shareholders."
He contrasted his approach with eBay's current leadership, saying, "I don’t get paid unless I build a much larger business and I want to turn eBay into something much larger."
He also took aim at eBay's expense structure.
"I mean, it’s a business that’s spending over $5.5 billion on $11 billion in revenue to run a business that essentially has no inventory and is very asset light," Cohen said, adding that he is "committed to $2 billion in cost cuts at eBay."
He Likes the BusinessCohen told Pompliano that he is prepared to keep pressing the matter directly with shareholders.
"We’re going to do whatever we obviously need to do in order to bring this proposal in front of the true owners of the business," he said.
Cohen summed up his eBay motivations simply: "I want the business. I want the business."
GME Price ActionThe chart below shows the one-year price action for GME:
GME Price Action: GameStop stock was down 0.22% at $22.34 at the time of publication on Wednesday, according to Benzinga Pro.
Over the past month, GME has declined about 4.53% versus a 9.5% rise in the S&P 500 and is up roughly 10% year-to-date compared to the index’s 8.2% gain.
Photo: Jillian Cain Photography / Shutterstock
Market News and Data brought to you by Benzinga APIs
SummaryCompaniesCohen presses eBay to let shareholders weigh in on offerCohen hints that he won't give up on effort to win eBayCohen calls eBay management "losers"NEW YORK, May 13 (Reuters) - GameStop (GME.N), opens new tab CEO Ryan Cohen told eBay's (EBAY.O), opens new tab board on Wednesday that they should not reject his $56 billion takeover proposal and the e-commerce company's shareholders deserve a chance to evaluate it.
Cohen reacted one day after eBay rejected his unsolicited offer to buy the company, calling the proposal "neither credible nor attractive."
The Reuters Daily Briefing newsletter provides all the news you need to start your day. Sign up here.
In a letter to eBay's chairman and separate online interview with journalist Piers Morgan, Cohen, a billionaire investor, signaled his intention to keep going and hinted at possible next steps to try and win his prize.
Revered by many retail investors for having faced off against prominent hedge funds while investing in GameStop, Cohen has previously said he would make cost cuts and considerable changes at eBay, including running the combined company himself.
Referring to eBay's board in the interview with Morgan, Cohen said: "They have a job to do their best for shareholders and engage on this and if they don't then we'll do whatever we need to do."
In the letter to eBay Chairman Paul Pressler, Cohen emphasized that eBay shareholders deserved a say on his proposal and went on to criticize top management's compensation.
"They should not dismiss a $125 per share proposal without engaging on its substance," he wrote, adding: "The economics are clear and they are public. eBay's own shareholders deserve the opportunity to evaluate them."
Ebay on Wednesday declined to comment beyond the statement it made on Tuesday.
GameStop owns a 5% stake in eBay and some analysts speculated Cohen may try to call a special shareholder meeting where he might try to get directors elected who might view his proposal more favorably. But they also noted he would need a considerably larger stake to make such a move.
Cohen also noted that he had requested a meeting with eBay's board but had been rejected, according to the letter which was seen by Reuters.
GameStop logo is seen in this illustration taken September 9, 2025. REUTERS/Dado Ruvic/Illustration/File Photo Purchase Licensing Rights, opens new tab
SURPRISE OFFEREarlier this month Cohen surprised Wall Street with his unsolicited offer to buy a company significantly bigger than his own when he offered $125 a share in cash and stock for each eBay share. GameStop has a market valuation of about $10 billion while eBay's market value is roughly $50 billion.
On Tuesday eBay pointed to concerns with GameStop's bid, including its financing, its impact on eBay's long-term growth and the leadership structure of a potentially combined company.
The GameStop CEO previously said he has a debt financing commitment letter from TD, contingent on the combined company receiving an investment-grade rating. Moody's said last week the deal would be credit negative for eBay.
Cohen's letter on Wednesday compared his tenure as leader at GameStop with eBay chief Jamie Iannone's six years at the helm. "He has received ~$144 million in compensation. He has not purchased a single share of eBay common stock in the open market," Cohen's letter said.
Cohen said about himself that he draws no salary, gets no cash bonuses and has no golden parachute. He said he has invested $128 million in GameStop common stock since 2020.
Some 88% of Iannone's compensation is delivered in eBay equity.
Analysts noted that eBay already has an EBITDA margin of 31%, three times higher than GameStop's 10%.
Cohen told Morgan: "I'm an owner-operator. I'm not one of these country club executives that get recruited through these professional agencies."
Referring to eBay, he said, "I love the asset," but added, "it's run by a bunch of losers."
Reporting by Svea Herbst-Bayliss; Editing by Nia Williams and Stephen Coates
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Abigail is on the M&A team and writes about consumer and retail deals. She joined Reuters in 2022 from Debtwire where she covered leveraged finance and the primary debt market for three years. Previously, her work has appeared in the Wall Street Journal, CNBC and the Boston Business Journal. She majored in business journalism at Washington and Lee University.
